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The Preface:
A thesis is more than a document to be read…

“I hope that my achievements in life shall be these—
that I will have fought for what was right and fair,
that I will have risked for that which mattered, and
that I will have given help to those who were in need,
that I will have left the earth a better place for what
I’ve done and who I’ve been.”
~ C. Hoppe
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Four years ago, I first stepped foot on the Regis University campus, and
since that time I have experienced many different thoughts, ideas, and theories
that have ultimately lead to this thesis. My time at Regis has been a time of
learning both inside and outside of the classroom. My academic path through
Regis has primarily revealed itself through the combination of three avenues of
learning: an education in neuroscience, the liberal arts core curriculum, and the
honors program curriculum. In addition to these avenues of learning, I have also
learned a great deal outside of the classroom through conversations with other
members of the Regis community, as well as my involvement on campus. The
goal for this thesis is to draw upon all aspects of my education, both academic
and non-academic, as well as integrate the values and beliefs that are at the core
of who I am as a human being.
The most influential portion of my life for the last four years has been the
time I have spent at Regis University. Most of my time at Regis has been spent in
the classroom or studying, as it should be; and most of my time in the classroom
has been spent in the neuroscience department, as it should be. All kidding aside,
I have gained a tremendous appreciation for the human brain, the nervous
system, and how these structures influence who we are as people during my
time at Regis. As a result of these interests, neuroscience has become my major,
-2-
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the focus of my education for the past few years, and now a primary focus of my
thesis project.
Although neuroscience has played a major role in my academic career, the
summation of all my areas of study has determined my overall, Regis education.
Regis University has a rather vast core curriculum, as it is a liberal arts college.
At times this has been a burden, as I would prefer to spend my time in the
neuroscience laboratory, but in retrospect, I am glad for the numerous disciplines
I have encountered. Regis emphasizes the importance of a well rounded
individual, and the core curriculum is one way of accomplishing this emphasis.
A person is only able to be knowledgeable in the world by knowing a little of
everything, and it is often true that one discipline will inform another, further
enhancing an individual’s intellectual prowess. I have learned that
interdisciplinary learning is the most challenging, but also the most rewarding
and applicable to the real world. Because of this, I have aimed to create an
interdisciplinary thesis, in which I not only approach a neuroscience topic but
some other aspect of the topic as well.
The final avenue of learning that has guided me through my education at
Regis has been the honors program. The honors program curriculum is
interdisciplinary in nature, but is also more than that. The honors program
-3-
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emphasizes the importance of asking one’s self very difficult questions. Such
questions include: how can tradition inform innovation, what is justice, and how
does one find meaning? These questions do not have universal answers, but they
must be thought about because of the ways that they inform an individual’s life.
Whether conscious or not, every individual must have a meaning for their life as
well as a clear conception of what is just. Without these beliefs, no individual
could carry out simple everyday tasks such as waking up in the morning or
going to work. One must have a purpose for his or her life, and then carry his or
her passion into all the work that he or she takes part in. Likewise, a person must
know how to live justly through his or her work, friendships, and every day
interactions. In summary, the honors program has helped me solidify my own
beliefs and encouraged me to continue asking questions that may or may not
have answers. In regards to this thesis, the honors program has confirmed my
belief that it must be interdisciplinary, but it also directed me to look for a thesis
topic that I find personally important.
Bringing all three of these avenues into conversation, I concluded that this
thesis should attempt to answer a challenging question, be interdisciplinary in
nature, be grounded in neuroscience, and most of all, be of value to me. In order
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to narrow in on the topic of this thesis, posttraumatic stress disorder, I looked to
my experiences outside the classroom.
A major influence in my life is my family, and a good portion of my
family is military. Additionally, I have thought heavily about joining the military
as I pursue a career as well. Thus, the military seemed to be an appropriate area
to explore. With some research and a lot of thought, I began to investigate
posttraumatic stress disorder. Through my neuroscience background, I had been
exposed to the tragedies of the disorder and the impairments that it may cause,
but it was not until I began investigating the disorder apart from neuroscience
and psychology that I fully realized the issues surrounding the disorder. For
instance, veterans and legislators have been in a heated agreement over the
question: should war veterans with PTSD be given a purple heart? This further
leads to an even greater question, how is physical injury different from mental
injury? The answer to this question is not easily answered, but it is generally
agreed upon that mental injury is indeed different than physical injury. Physical
injury, no matter how severe, will not change the person’s personality,
perceptions, or memories unless there is a mental side effect to the physical
damage. On the contrary, mental injury has a great impact on all these aspects of
the person’s identity. From this stance, I decided to explore the possibilities of
-5-
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treating PTSD. In almost all circumstances, a person will correct a physical injury
if possible. With PTSD, however, this is not an option. Although there is ample
research looking into treatments for PTSD, there currently is not a treatment to
prevent or relinquish PTSD symptoms. Due to my personal connection to the
military, I decided to contribute to PTSD research and study the effects of
propranolol (an experimental drug) on PTSD symptoms. In short, I see the
ultimate goal of PTSD research, and my thesis, as helping those suffering from
PTSD cope with the disorder and possibly restore their pre-trauma quality of
living.
The foundation of my thesis is to experimentally test the effects of
propranolol as it relates to PTSD symptoms. However, this does not fulfill all the
requirements I had set for myself in creating this thesis project. From the time I
began proposing my experiment, I also began to question the possible impacts of
a drug that would treat PTSD. How could a drug simply wipe away one’s
memory or completely dissociate the emotional impact of such a memory? And
if this could really happen, should it? Much of my life has been informed by the
memories I have. I believe that I am not simply one person, but a summation of
every person I have been at each point in my life. In other words, I am who I am
because of my experiences; my value of memory is very high. Thus a personal
-6-
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conflict arises. I have a desire to help suffering individuals, but through certain
forms of helping, one may remove key elements of that person’s identity and
alter his or her future self. At this cost, is treating the disorder still helping? In this
conflict, I discovered the second portion of this thesis. Through asking tough
questions, such as what is the value of suffering, how can one give informed
consent for such a treatment, and how does religion impact such a treatment
decision, I decided to explore whether treating PTSD would be ethically possible,
and if so, would the treatment of PTSD bring justice to the victim.
This thesis is my attempt to give attention to a topic that is controversial,
but also deeply rooted in the lives of many. At the conclusion of this thesis, I
would like to have a universal answer to the questions I have raised, but I cannot
guarantee this will be the result. What I can guarantee is that I will have a greater
understanding of the topic and will have insights that I did not have at the start
of this project. I also hope that you gain a better understanding of the topic at
hand as a result of my work here. It is true that a thesis is more than a document
to be read. A thesis springs from a need or question in the world, and has the
potential to create a change. In conclusion, I propose that we all ask the tough
questions and begin to seriously consider the impacts of the decisions we make
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whether they be monumental, such as treating a patient with PTSD, or every day,
such as helping a neighbor in need.
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An introduction to posttraumatic stress disorder (PTSD):
The history, etiology, and treatment strategies
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The popular expression “What does not kill you makes you stronger”
points to some people’s ability to respond to trauma resiliently. However, for
those same traumas, a more appropriate statement may be “What does not kill
you can make you ill” or “What does not kill you might as well have.” There are
many individuals who are not resilient to trauma, and when faced with a
traumatic experience, their lives are forever altered. Even those who are highly
resilient may develop a serious psychological disorder depending on the severity
of the trauma. Approximately one tenth of those who survive life-threatening
events will develop a mental health disorder, such as posttraumatic stress
disorder (PTSD) (Jovanovic & Ressler, 2010). Although PTSD was once thought
to be relatively uncommon, recent estimates suggest that between 10 and 39
percent of all people will suffer from PTSD during their lives (Cantor, 2005, p.7).
PTSD is a serious issue, and is one that needs to be addressed.
Although the diagnostic criteria for PTSD have only been in place since
1980, the symptoms associated with PTSD have been around for much longer.
Symptoms associated with PTSD, such as high levels of anxiety, heightened
startle response, nightmares, and emotional reliving of experiences have existed
since the pre-Christian period (Parry-Jones & Parry-Jones, 1994). Although PTSD
is no longer a new term, the disorder has been around for a much longer period
- 10 -
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under other pseudonyms. Since the mid-nineteenth century, PTSD-type
symptoms have been given numerous titles such as: spinal concussion, railway
spins, and irritable heart from the 1860s; soldier’s heart and cardiac weakness
from the 1870s; traumatic shock, traumatic neurosis, hysterical hemianaesthesia,
spinal irritation, railway brain, and nervous shock from the 1880s; anxiety
neurosis and psychical trauma from the 1890s; traumatic neurosis, shell fever,
irritable heart of soldiers, mental shock, war shock, shell shock, neuro-circulatory
asthenia, disordered action of the heart, and war psychoneurosis from the 1910s;
cardiac/war neurosis form the 1930s; and battle fatigue/combat exhaustion and
effort syndrome from the 1940s (Parry-Jones and Parry-Jones, 1994). Each of
these terms referred to what is now known as posttraumatic stress disorder. It
was not until 1980, when posttraumatic stress disorder was added to the third
edition of the Diagnostic and Statistical Manual for Mental Disorders that PTSD
became a generally accepted term for such abnormal responses to severe trauma
(Cantor, 2005).
The Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR)
provides the following diagnostic criteria for PTSD (2000). For an individual to
be diagnosed with PTSD, the person must have been exposed to a traumatic
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event in which the person experienced, witnessed, or was confronted with an
event or events that involved actual or threatened death or serious injury, or a
threat to the physical integrity of self or others. Additionally, the person’s
response to the experience must involve intense fear, helplessness, or horror. The
victim must also persistently re-experience the traumatic event through visual
images, thoughts, dreams, or mental recreation of the event. The person must
avoid stimuli associated with the trauma and have persistent symptoms of
increased arousal. Finally, the duration of the disturbance must be more than one
month (American Psychiatric Association [DSM-IV-TR], 2000). These are the
symptoms that an individual must present to be classified as experiencing PTSD.
PTSD-influencing traumas are more common than one may think. Such
traumatic experiences do not only happen during war or high conflict situations,
but also during everyday life. For example, several of the earlier terms for PTSD
involved the railway due to the traumatic scenes of train crashes during that time
period. One notable victim of such a crash was Charles Dickens. A train crash left
his carriage swaying precariously from a bridge, and upon emerging from his
carriage he was greeted with the sight of dead and injured all around him
(Cantor, 2005). Although PTSD was not recognized as a diagnosis at the time,
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Charles Dickens’ experiences in the train crash nearly 150 years ago closely
resemble what many sufferers of acute stress and PTSD go through today.
Although people who have been tortured and/or victimized for long
periods of time suffer the highest rates of PTSD and that prisoners of war and
concentration camp survivors have a 50% rate of chronic PTSD, the prevalence of
PTSD resulting from other everyday-type traumatic experiences is significant as
well (Cantor, 2005). Civilians too face surprisingly high rates of exposure to
traumatic stressors during their normal, everyday routine, including rape,
terrorist attacks, death of a loved one, childhood abuse, natural disasters, and a
wide variety of other severe psychological traumas (Heim & Nemeroff, 2009).
Survivors of natural disasters have rates of PTSD around 4% (Cantor, 2005). 12%
of individuals involved in a motor vehicle accident, which has a lifetime
prevalence of 23%, develop PTSD (Cantor, 2005). Assault is another trauma
which may result in PTSD. Thirty percent of non-sexual assault case victims and
50% of rape victims will develop PTSD within three months of the trauma
(Cantor, 2005). Traumas associated with war and combat are leading causes of
PTSD, but traumas of everyday life also lead to PTSD symptoms. These PTSD
causing trauma are linked by their uncontrollability.
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When all the possible PTSD-producing traumatic events are summed
together, the prevalence of PTSD shows itself to be quite high. Posttraumatic
stress disorder is a serious anxiety disorder with a lifetime prevalence of
approximately 6.8% in the United States and a 12 month prevalence of 3.8%
(Adamec, Muir, Grimes, & Pearcey, 2007). Given that 50-60% of all North
Americans experience a traumatic stress in their lifetimes, and 15% of these
traumatically stressed individuals will subsequently develop PTSD, PTSD has
become a serious issue and the topic of much research (Adamec, Muir, Grimes, &
Pearcey, 2007). Further enhancing the need for a better understanding of PTSD is
the fact that approximately 30% of patients experiencing PTSD will still be
suffering from the disorder at least ten years after the trauma (Langevin, De
Salles, Kosoyan, & Krahl, 2010). This is highly troubling because research has
shown that if PTSD symptoms have not been resolved within 6 years, the
symptoms are highly likely to remain chronic (Cantor, 2005).
Currently, the three most common treatment methods for PTSD are
cognitive behavior therapy, eye movement desensitization and reprocessing
(EMDR), and stress management (Ponniah & Hollon, 2009). Trauma-focused
cognitive behavior therapy involves repeated exposure to the traumatic memory
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through cognitive methods and then progressively changing the individual’s
thought processes and behaviors towards the trauma. EMDR utilizes dual
attention tasks to help the patient process the traumatic event. EMDR involves
the patient focusing on negative trauma-related memories while engaging in a
task involving some form of bilateral stimulation, such as eye movements, until
distress has decreased and belief in more positive trauma-related thoughts has
increased. Stress management does not focus on the trauma, but involves the
patient’s learning skills to help manage anxiety. Such skills consist of slow,
abdominal breathing, relaxation techniques, learning to use positive statements
and self-talk strategies, distraction techniques, and assertiveness training.
Although these three treatments prove helpful for some patients suffering
from PTSD, 30% of patients who develop PTSD will still be suffering from
treatment ten years following the trauma (Langevin, De Salles, Kosoyan, &
Krahl, 2010, p. 1241). This prevalent rate reflects that the current treatments for
PTSD do not meet all of the needs of those affected. Although there have been
significant advances in the understanding of PTSD, treatment failures persist. As
a result, researchers have subsequently begun studying the effects of possible
pharmacological interventions.

- 15 -
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While the goal of any study focusing on a disease or disorder is to find a
cure, the mechanisms through which the disorder or disease arises must first be
understood so that an effective treatment may be found. It is generally accepted
that the symptoms of PTSD reflect stress-induced changes in neurobiological
systems and/or an inadequate adaptation of neurobiological systems to exposure
of severe stressors. However, it is not clear which specific neurological systems,
neurotransmitters, or brain structures are affected by the traumatic experience(s),
and subsequently, elicit PTSD.
Various aspects of the nervous system have been implicated in the
pathophysiology of PTSD, including the hypothalamic-pituitary-adrenal (HPA
axis), the hippocampus, the amygdala, the prefrontal cortex, as well as six
neurotransmitters and neuropeptides. Each of these brain structures, systems,
and neurotransimtters play a role in the regulation of fear, the response to stress,
or memory consolidation, and have attracted much attention regarding the study
of the etiology of PTSD and the any potential treatments for the disorder.
The neurocircuitry that has been scrutinized most closely in PTSD patients
has been the HPA axis, an organism’s major neuroendocrine stress response
system (Heim & Nemeroff, 2009), which is responsible for coordinating the
- 16 -
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body’s response to stress (Yehuda, 2000). Upon exposure to a stressor, neurons in
the hypothalamic paraventricular nucleus (PVN) secrete corticotrophin-releasing
factor (CRF). CRF is then transported to the anterior pituitary where it stimulates
the production of adrenocoricotropin (ACTH). ACTH, in turn, stimulates the
release of glucocorticoids from the adrenal cortex. Glucocorticoids exert effects
on metabolism, immune function, and the brain to adjust physiological functions
and behavior to the stressor (Heim & Nemeroff, 2009). In short, a stressor affects
a cascade of hormones that eventually results in the release of cortisol from the
adrenal cortex, which functions to manage the body’s biological stress response
by stimulating the termination of neural defense reactions that have been
activated by stress (Yehuda, 2000). These mechanisms cause the HPA axis to be
the major system in which trauma is managed.
Studies of the HPA axis in patients with PTSD have revealed low cortisol
levels in patients with PTSD regardless of the type of trauma, an individual’s age
at traumatization, the duration of PTSD symptoms, or the age of the subjects at
the time of biological assessment (Heim & Nemeroff, 2009; Yehuda, 2000).
Cortisol serves a regulatory function in the CNS. Decreased cortisol levels result
in PTSD because less cortisol equates to an individual’s lessened ability to
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manage their biological response to trauma. This inability to manage one’s
biological response to trauma results in the sustained activation of neural
systems involved is stress reactivity and fear processing (Heim & Nemeroff,
2009). All considered, it seems that cortisol levels are directly associated with the
severity of PTSD symptoms.
Several brain pathways modulate HPA axis activity. The hippocampus
and prefrontal cortex inhibit the HPA axis, whereas the amygdala and
monoaminergic input from the brainstem stimulate the activity of neurons
associated with the HPA axis (Heim & Nemeroff, 2009), creating an interest in
these pathways as well. The most reproducible finding in structural imaging
studies of PTSD is reduced volume of the hippocampus. The hippocampus is
implicated in the control of stress responses, declarative memory and contextual
aspects of fear conditioning (Heim & Nemeroff, 2009). A preponderance of
neuroimaging data from the past decade demonstrates that PTSD patients have
greater amygdala activation relative to comparison subjects; brain imaging
studies (PET and fMRI) have found that the amygdala modulates the fear
response (Jovanovic & Ressler, 2010). Furthermore, recent functional magnetic
resonance imaging (fMRI) studies have found that trauma-relevant words as
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well as trauma-specific imagery increase amygdala activation (Jovanovic &
Ressler, 2010). In much the same way, the prefrontal cortex is implicated in
PTSD. Recent studies have demonstrated that neurons in the prefrontal cortex
have inhibitory action on the amygdala (Jovanovic & Ressler, 2010). Exaggerated
fear responses observed in PTSD and the impaired inhibition on conditioned
inhibition tasks is thought to be due to a weakened inhibitory control of the
amygdala by the prefrontal cortex in combination with a lack of control over
stress responses due to alterations in hippocampal volume. Ultimately, several
brain regions are currently implicated in PTSD.
Yet, like most mental disorders, it is likely that the unfavorable stress
response to a traumatic event in PTSD is influenced by an imbalance in
neurotransmitters, whether due to overproduction, inactivation, or an alteration
at the receptor sites. Several neurotransmitters and neuropeptides are involved
in the body’s response to stress, and thus, are of interest in PTSD research. The
implicated neurotransmitters are norepinephrine, serotonin, GABA, glutamate,
neuropeptide Y, and opioids (Heim & Nemeroff, 2009). Norepinephrine is
believed to play the greatest role in an individual’s response to trauma and the
memory consolidation of such trauma.
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Before discussing norepinephrine, the effects of serotonin, GABA,
glutamate, neuropeptide Y, and opiods as related to PTSD symptoms should be
discussed. Serotonin helps to regulate sleep, appetite, sexual behavior,
aggression and impulsivity, motor function, and neuroendocrine control (Heim
& Nemeroff, 2009). Serotonin neurons of the dorsal raphe projecting to the
amygdala and hippocampus mediate stress-increasing effects via serotonin
receptors (Heim & Nemeroff, 2009). Chronic exposure to stressors induces
upregulation of these serotonin receptors (Heim & Nemeroff, 2009). Altered
serotonin transmission may contribute to a subset of the symptoms of PTSD that
includes hypervigilance, increased startle response, impulsivity, and intrusive
memories. Additionally, treatment with GABA agonists decreases symptoms of
anxiety in PTSD, and exposure to stressors increases glutamate release in the
brain (Heim & Nemeroff, 2009). Neuropeptide Y inhibits CRF and
norepinephrine circuits involved in stress and fear responses (Heim & Nemeroff,
2009). Thus, a lack of neuropeptide Y promotes a maladaptive stress response
and contributes to the development of PTSD (Heim & Nemeroff, 2009).
Endogenous opioids such as endorphins or enkephalins inhibit the HPA axis,
and alterations are involved in symptoms of numbing, stress-induced analgesia,
and dissociation in PTSD (Heim & Nemeroff, 2009). Opiates have the ability to
- 20 -
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dampen central noradrenergic hyperactivity, and consequently PTSD symptoms
(Strawn & Geracioti, 2008). Clearly, neurotransmitters are not without an effect
on the development and sustainment of PTSD.
The major stress response neurotransmitter is norepinephrine.
Norepinephrine is the major central catecholamine, and is derived from neurons
of the locus coeruleus. These neurons project to many structures that are
involved in the pathophysiology of PTSD. Structures affected by norepinephrine
include the prefrontal cortex, amygdala, hippocampus, hypothalamus,
periaqueductal gray matter and thalamus (Liberson et al., 1999; Phan et al., 2006;
Pissiota et al., 2002). Norepinephrine largely affects the regulation of arousal and
autonomic stress responses. Norepinephrine (NE) is produced by the adrenal
medulla through sympathetic stimulation and the local effects of cortisol, and
provides positive feedback to the pituitary gland maintaining the stress response
and further stimulating the HPA axis (Vermetten & Bremner, 2002).
Norepinephrine is also thought to play a role in the encoding of memories
(Vermetten & Bremner, 2002). Norepinephrine exerts it effects by binding to
alpha or beta adrenoreceptors. Beta receptors are linked to G-protein systems,
and promote its effects by the increase of adenylyl cyclase. In contrast, alpha
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receptors are associated with a myriad of biochemical effectors; alpha receptors
effects are also transduced through a G-protein system (Strawn & Geracioti,
2008). To reduce the effects of norepinephrine at each of these receptors,
antagonists for each of the receptors may be introduced. Although antagonist for
alpha as well as beta receptors have proved effective at reducing the effects of
norepinephrine, beta blockers are more centrally acting (Strawn & Geracioti,
2008). Norepinephrine has been a central candidate in studying the
pathophysiology of PTSD (Heim & Nemeroff, 2009).
Combat veterans, abused women, and children with PTSD have increased
levels of norepinephrine in their urine (Heim & Nemeroff, 2009). A couple of
studies have investigated the excretion of catecholamines following sexual abuse.
De Billis et al. (1994) found increased levels of norepinephrine 24 hours after the
abuse, and Lemieux and Coe (1995) documented increased levels of
norepinephrine excretion later in life for the individuals who go on to develop
PTSD related to childhood sexual abuse. Likewise, combat veterans with PTSD
show increased levels of norepinephrine excretion 24 hours after trauma
compared to patients with major depression, bipolar mania, paranoid
schizophrenia, undifferentiated schizophrenia, and healthy control subjects
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(Kosten et al., 1987; Yehuda et al., 1992). While many studies have assessed
urinary concentrations of norepinephrine, not all of them have observed
increased levels of norepinephrine in patients with PTSD (Glover and Loland,
2002). This finding is likely due to norepinephrine’s inability to cross the bloodbrain barrier. Peripheral concentrations do not well reflect norepinephrine
concentrations (Strawn & Geracioti, 2008). Patients with PTSD have tonically
elevated norepinephrine concentrations in the central nervous system, and
central nervous system norepinephrine is robustly secreted in response to acute
psychological stress (Geracioti et al., 2001). Clinically, evidence shows that
norepinephrine plays a role in an individual’s response to stress, and if PTSD
develops, increased amounts of norepinephrine are produced.
Based on its strong role in the body’s stress response systems,
norepinephrine has been a central target in researchers’ attempts to develop a
preventative treatment for PTSD. One of these norepinephrine-targeting drugs is
a long-chain beta-blocker called propranolol. Propranolol is a non-selective betaadrenergic antagonist that binds to peripheral and central β-adrenergic receptors
and readily crosses the blood-brain barrier (Vaiva et al., 2003). Thus, propranolol
may be used to block β-noradrenergic receptors in the amygdala after fear
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memory training blocks consolidation of the fear memory. Although attempts to
mitigate PTSD symptoms with post stressor block of β-noradrenergic receptors
with propranolol have been successful (Pitman et al., 2002; Reist et al., 2001;
Vaiva et al., 2003), some research has found propranolol ineffective in treating
PTSD symptoms (Cohen et al., 2011). For example, Pitman et al. (2002) reported
that propranolol given within 6 hours of a traumatic event for 10 days was
superior to a placebo for reducing PTSD symptoms 1 month after trauma.
Similarly, Vaiva and colleagues (2003) found that when compared to eight
traumatized patients who did not receive propranolol, only one in 11 treated
patients developed PTSD developed PTSD two months after the trauma,
whereas PTSD developed in three of the eight untreated patients. Evidence has
been reported that administration of propranolol shortly after exposure to
psychological trauma reduces PTSD symptom severity and reactivity to
reminders of the traumatic event (Heim & Nemeroff, 2009). The present study
will test propranolol as an experimental treatment for PTSD as defined in a rat
model.
Although several studies have experimentally tested PTSD in human
trauma victims and the results have shown to affect PTSD symptoms, the
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research is not conclusive that propranolol is an effective treatment to prevent
PTSD. This study will attempt to influence an animal model of PTSD, and
subsequently test propranolol as a preventative treatment for PTSD-like
symptoms in rats exposed to a life-threatening stressor.
The criteria for influencing PTSD in an animal model should include the
same criteria as deemed necessary for a diagnosis of PTSD by the DSM-IV-TR.
There should be the application of direct physical stressors in conjunction with
exogenous stimuli that closely mimic those seen in nature. Furthermore, the
stressors should influence a fear for one’s life. When these criteria are followed,
stressed rats tend to show PTSD-like behavior such as increased immobility,
decreased grooming and rearing, decreased exploratory behavior and decreased
food consumption (Kesner et al., 2009). Thus, fear conditioned behavior, which is
similar to PTSD symptoms, should be able to be accomplished via the
implementation of appropriate stressors. It should be noted that chronic PTSD
cannot be elicited in animals due to the ethical constraints that are put on the
mistreatments that may be put on animals for scientific purposes. In most cases,
conditioned fear is taken as the animal model of PTSD.
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The present study will first strive to develop an animal model of PTSD in
rodents, and then attempt to evaluate the effects of propranolol on PTSD-like
symptoms. In the present study, rats will be exposed to inescapable shocks at a
rate of one shock per thirty seconds for ten minutes on a variable interval
schedule. This direct stressor will be paired with the scent of bobcat urine in
order to create a trauma eliciting PTSD. Rodent behavior - levels of anxiety,
burying behavior, and freezing behavior - will be observed pre- and post- trauma
to indicate whether rat behavior has changed in response to the traumatic
experience. Given that the rodent behavior does change, propranolol will then be
used as a treatment for PTSD symptoms. All in all, this study will address three
guiding questions for the research: 1) Can an accurate animal model for PTSD be
developed? 2) Does propranolol, a β-noradrenergic antagonist, reduce PTSD
symptoms? 3) Does propranolol reduce PTSD symptoms via the blockage of βnoradrenergic receptors in the brain?
My hypotheses are that (1) PTSD behavior will be altered in response to a
traumatic experience, and subsequently that symptoms similar to PTSD behavior
can be observed in an animal model, (2) propranolol will effectively reduce the

- 26 -

PROPRANOLOL AND PTSD

severity of PTSD symptoms, and (3) propranolol prevents the development of
PTSD through interference with adrenergic receptors in the amygdala.
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THE EFFECTS OF PROPRANOLOL,
A NON-SELECTIVE β-ADRENERGIC ANTAGONIST,
ON RAT BEHAVIOR IN AN ANIMAL MODEL OF
POSTTRAUMATIC STRESS DISORDER
Joshua R. Kniss and Mark Basham, Ph.D.

Abstract: To date, very little is known about the neurocircuitry of posttraumatic
stress disorder, and currently 5.2 million people are suffering from PTSD in the
United States alone. In hopes to treat PTSD symptoms, researchers have targeted
corticosteroids, beta-adrenergic antagonists, and opiate analgesics to reduce
hormonally enhanced memories and fear conditioning. This study focuses on
testing propranolol, a beta-adrenergic antagonist, as a treatment for PTSD-like
symptoms (anxiety and freezing behavior) in a rat model. Rats were exposed to
inescapable, moderate shocks paired with a predator scent to elicit PTSD-like
symptoms. Propranolol was shown to effectively reduce anxiety at 28 days post
stress, but did not affect freezing behavior. Through this study, data concerning
the time course for PTSD in an animal model was obtained.
Key words: posttraumatic stress disorder; norepinephrine;
propranolol; β-blocker

- 28 -

PROPRANOLOL AND PTSD

death of loved ones, childhood
abuse, natural disasters, and several
other severe psychological traumas
(Heim & Nemeroff, 2009). Whatever
the trauma, all traumatic events are
marked by uneasy memories or
thoughts of the ordeal, emotional
instability, increased arousal, and/or
personality changes (Heim &
Nemeroff, 2009). However,
additional symptoms may develop.
The Diagnostic and Statistical
Manual for Mental Disorders (DSMIV-TR) provides diagnostic criteria
for PTSD (American Psychiatric
Association [DSM-IV-TR], 2000). For
an individual to be diagnosed with
PTSD, the person must have been
exposed to a traumatic event in
which the person experienced,
witnessed, or was confronted with
an event or events that involved
actual or threatened death, serious
injury, or a threat to the physical
integrity of self or others (American
Psychiatric Association [DSM-IVTR], 2000). The person’s response to
the experience must involve intense
fear, helplessness, or horror. The
victim must persistently reexperience the traumatic event
through visual images, thoughts,
dreams, or mental recreation of the
event. The individual must avoid
stimuli associated with the trauma
and have persistent symptoms of
increased arousal. Finally, the

1. Introduction
The popular expression
“What does not kill you makes you
stronger” points to the fact that some
people respond to trauma resiliently.
While this response may be true for
highly resilient people, a more
appropriate general statement may
be “What does not kill you can make
you ill” or “What does not kill you
might as well have.” Many
individuals are not resilient to
trauma, and when faced with a
traumatic experience, their lives are
forever altered. Even those who are
highly resilient may develop a
serious psychological disorder
contingent on the severity of the
trauma. Approximately one tenth of
those who survive life-threatening
events will develop a mental health
disorder, such as posttraumatic
stress disorder (PTSD) (Jovanovic &
Ressler, 2010). This equates to 5.2
million people suffering from PTSD
in the United States (Adamec, Muir,
Grimes, & Pearcey, 2007).
In general terms, PTSD is a
debilitating psychological condition
triggered by a major traumatic event.
In addition to war, the stereotypical
traumatic experience leading to
PTSD, civilians in modern societies
also face surprisingly high rates of
exposure to traumatic stressors,
including rape, terrorist attacks, the
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duration of the disturbance must be
more than one month (American
Psychiatric Association [DSM-IVTR], 2000).
Posttraumatic stress disorder
is a serious anxiety disorder with a
lifetime prevalence of approximately
6.8% in the United States and a 12
month prevalence of 3.8%. 50-60% of
all North Americans experience a
traumatic stress in their lifetimes,
and 15% of these traumatically
stressed individuals will
subsequently develop PTSD
(Adamec, Muir, Grimes, & Pearcey,
2007). Furthermore, approximately
30% of patients will still be suffering
from PTSD at least ten years after the
trauma (Langevin, De Salles,
Kosoyan, & Krahl, 2010). This
finding is highly troubling because
research has shown that if PTSD
symptoms have not been resolved
within 6 years, the symptoms are
highly likely to remain chronic
(Cantor, 2005).
The symptoms of PTSD reflect
stress-induced changes in
neurobiological systems and/or an
inadequate adaptation of
neurobiological systems to exposure
to severe stressors. However, it is not
clear which specific neurological
systems, neurotransmitters, or
abnormal brain structures cause
PTSD. Neurobiologicial systems that
have been implicated in the

pathophysiology of PTSD include
the hypothalamic-pituitary-adrenal
(HPA) axis, and various
neurotransmitters and
neuropeptides that comprise a
network of brain regions that
regulate fear and stress responses.
These include the prefrontal cortex,
hippocampus, amygdala, and
brainstem nuclei (Heim & Nemeroff,
2009). The neurocircuitry that has
been scrutinized in PTSD patients
has been the HPA axis. The HPA
axis is an organism’s major
neuroendocrine stress response
system which affects metabolism,
immune function, and the brain,
adjusting physiological functions
and behavior to stress (Heim &
Nemeroff, 2009). The HPA axis'
sensitivity is increased after a
traumatic event by a strong negative
feedback of cortisol which is due to
the highly increased sensitivity of
cortisol receptors (Heim & Nemeroff,
2009). Another mediator of HPA axis
activity is norepinephrine.
Norepinephrine (NE) is produced by
the adrenal medulla through
sympathetic stimulation and the
local effects of cortisol, and provides
positive feedback to the pituitary
gland maintaining the stress
response and further stimulating the
HPA axis (Vermetten & Bremner,
2002). Norepinephrine is also
thought to play a role in the
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encoding of memories (Vermetten &
Bremner, 2002).
The present study will focus
primarily on the development and
course of PTSD as it relates to the
secretion of NE. Because of its
multiple roles in regulating arousal
and autonomic stress responses
through its interaction with the HPA
axis, as well promoting the encoding
of emotional memories, NE has been
a central candidate in studying the
pathophysiology of PTSD (Heim &
Nemeroff, 2009). NE is one of the
principal mediators of the central
nervous system (CNS) and
autonomic stress responses. The
majority of CNS NE is derived from
neurons of the locus ceruleus (LC)
that project to various brain regions
involved in the stress response,
including the prefrontal cortex,
amygdala, hippocampus,
hypothalamus, periaqueductal grey,
and thalamus (Heim & Nemeroff,
2009). Accordingly, increased
urinary excretion of NE and
epinephrine has been documented in
combat veterans, abused women,
and children with PTSD (Strawn &
Geracioti, 2008).
Many approaches to the
treatment of PTSD have been taken,
in animal models as well as in
humans. While the diagnostic
criteria for PTSD have only existed
since 1980, hundreds of clinical trials

have sought to identify methods of
ameliorating its distressing
symptoms (Cukor, Spitalnick,
Difede, Rizzo, & Rothbaum, 2009).
Current treatments for PTSD include
psychological interventions
including social and family based
therapy, behavioral treatments,
imagery-based treatments, therapies
focusing on distress tolerance,
“power” therapies, and
technological-based treatments
(Cukor et al., 2009). Although there
have been significant advances in the
treatment of PTSD, treatment
failures persist.
Another form of treatment is
pharmacological treatment, and is
the focus of recent research
pertaining to PTSD treatment and
prevention. Over the past decade,
many compounds have been tested
as treatments for PTSD.
Corticosteroids, beta-adrenergic
antagonists, and opiate analgesics
have been shown experimentally to
reduce hormonally enhanced
memories and fear conditioning
(Cohen, Kozlovsky, Matar, Kaplan,
& Zohar, 2010). Propranolol, a betaadrenergic antagonist, has received
great attention, and is hypothesized
to decrease the consolidation of
stressful memories due to its
inhibitory affects on NE receptors,
and indirectly the HPA axis.
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The focus of the present study
is on the efficacy of propranolol as a
preventative treatment for the
development of PTSD following a
traumatic experience. Propranolol is
a non-selective beta-adrenergic
antagonist that binds to peripheral
and central β-adrenergic receptors
and readily crosses the blood-brain
barrier (Vaiva et al., 2003). Thus,
propranolol may be used to block βnoradrenergic receptors and the
consolidation of the fear memory.
Attempts to mitigate PTSD
symptoms with post stressor block
of β-noradrenergic receptors by
treatment with propranolol have
mixed results, but there is evidence
that propranolol reduces PTSD
symptom severity (Pitman et al.,
2002; Reist et al., 2001; Vaiva et al.,
2003). Propranolol given within 6
hours of a traumatic event for 10
days was superior to a placebo for
reducing PTSD symptoms 1 month
after trauma (Pitman et al., 2002).
Vaiva and colleagues studied motorvehicle accident survivors and the
effects of propranolol on the
development of PTSD. Vaiva et al.
found that in comparison to eight
traumatized patients who did not
receive propranolol, treatment with
propranolol was superior. Only one
in 11 treated patients developed
PTSD two months after the trauma,
whereas PTSD developed in three of

the eight untreated patients (Vaiva et
al., 2003). Although some research
has found propranolol ineffective in
treating PTSD symptoms (Cohen et
al., 2011), the majority of evidence
has found that the administration of
propranolol shortly after (or before)
exposure to psychological trauma
reduces PTSD symptom severity and
reactivity to reminders of the
traumatic event (Heim & Nemeroff,
2009).
This study attempts to
determine the effectiveness of
propranolol as a preventative
treatment for PTSD symptoms. In
order to accomplish this, an animal
model of PTSD was influenced, and
the treatment tested in the animal
population. To date, little research
has been completed in an animal
model.
The criteria for inducing
PTSD in an animal model should
include the same criteria as a
diagnosis of PTSD by the DSM-IVTR. There should be the application
of direct physical stressors in
conjunction with exogenous stimuli
that closely mimic those seen in
nature. Furthermore, the stressors
should create a fear for one’s life.
When these criteria are followed,
stressed rats tend to show PTSD-like
behavior such as increased
immobility, decreased grooming and
rearing, decreased exploratory
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behavior and decreased food
consumption (Kesner et al., 2009).
The present study strives to
develop an animal model of PTSD in
rats, and then attempt to evaluate
the effects of propranolol on PTSD
symptoms. Rats are exposed to
inescapable shocks paired with the
scent of bobcat urine in order to
create a trauma eliciting PTSD. Rat
behavior (levels of anxiety, burying
behavior, and freezing behavior) is
observed pre- and post-stress to
indicate whether rat behavior has
changed in response to the traumatic
experience. Given that rodent
behavior changes, propranolol is
used as a treatment for PTSD
symptoms. All in all, this study
addresses two guiding questions for
the research: 1) Can an accurate
animal model for PTSD be
developed? and 2) Does propranolol,
a β-noradrenergic antagonist, reduce
PTSD symptoms in a rat model?
My hypotheses are that (1) rat
behavior will be altered in response
to a traumatic experience, and
subsequently that symptoms similar
to PTSD behavior can be observed in
an animal model and (2) propranolol
will effectively reduce the severity of
PTSD symptoms.

2. Method
All procedures were carried out
under strict compliance with ethical
principles and guidelines of the NIH
Guide for the Care and Use of
Laboratory Animals. All treatment
and testing procedures were
approved by the Intuitional Animal
Care and Use Committee of Regis
University in Denver, Colorado.
2.1. Animals
Adult, female SpragueDawley rats were used throughout
the study. The animals were housed
singly or in pairs in a cage with a
width of 10 inches, a length of 18.5
inches, and a height of 8 inches. The
conditions in the animal facility were
controlled at 72 oF. The animals were
held in an environment with a
twelve hour light – twelve hour dark
cycle (06:00—18:00 light). All
animals had food and water
available ad libitum. The cage
bedding was changed every 2-3
days.
2.2. Experimental design
The study consisted of two
main experiments, each assessing the
effectiveness of propranolol as a
treatment for post-traumatic stress
disorder in an animal model but
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differing in the behaviors assessed.
The independent variables were the
stress and treatment conditions. The
stress conditions were either stress
exposure or no stress exposure. The
treatment conditions were either no
treatment, a saline injection, or a
propranolol injection. The dependent
variables were the rats’ ball burying
behavior, elevated plus maze
performance, and freezing behavior.

after the stressors during Part 1 of
the experiment.
Part 2 of Experiment 1,
followed the same protocol.
However, after the stress exposure
period, the animals were
immediately injected with a 10
mg/kg dose of propranolol
intraperitoneally.
To evaluate whether the rats
developed PTSD-like behavior, two
assessment strategies were used in
Part 1 of Experiment 1, and all
assessment was completed at 7 days
as well as 28 days post stress
exposure. First, the novel object, the
soft-flight golf ball, was placed back
with the rat, in its normal living
conditions, for fifteen minutes, to
assess the rat’s burying behavior.
Rats bury a novel object when it has
been paired with a traumatic
experience (Harvey et al., 2006). The
second assessment tool was an
elevated plus maze, which was used
to assess anxiety. The dimensions of
the maze were 64.5 inches by 64.5
inches. Each arm was 30 inches in
length.

2.2.1 Experiment 1
Experiment 1 consisted of two
parts. Part 1 intended to develop an
animal model of PTSD. Rats were
randomly assigned to one of two
conditions, an inescapable stressor
condition or a control condition. In
the inescapable stressor condition,
each rat was exposed to moderate
shocks (shocks of 0.5 second
duration and 1.5 mA intensity)
occurring at 30 second variable
intervals for 10 minutes, combined
with a predator stress, bobcat urine.
All stress exposures occurred in a
standard operant chamber. During
the stress exposure period, the rat
was exposed to a novel object, a softflight golf ball. The control animals
were exposed to fresh, unsoiled
cedar chips and received no shock,
but were exposed to the novel object.
Neither the experimental rats nor the
control rats received any treatment

2.2.2. Lever pressing training
protocol
Prior to the start of
Experiment 2, the animals were
trained to press a lever in the
operant chamber for a sugar pellet
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reward. The training process shaped
the rats’ behavior. Each rat was
placed in an operant chamber and
shaped to stay the one side of the
chamber with the levers, then to rear
up on that side of the chamber, and
eventually to press the right or left
lever. When a rat performed a
desired behavior, it was rewarded
with a sugar pellet reward.
Lever pressing behavior was
reinforced until the animal was able
to receive at least 50 sugar pellets
within 20 minutes; first at a ratio of
one lever press to one sugar pellet,
and then at a ratio of 5 lever presses
to one sugar pellet. To achieve this
level of conditioning, four successful
reinforcement trials were utilized.
Each animal was placed in an
operant chamber and allowed to
receive 50 sugar pellets for itself via
pressing either the left or right lever.
Once this mark had been reached in
two successive trials, the animal was
removed from the chamber. After
two trials of training on the one lever
press to one sugar pellet fixed ratio,
the animal was trained to press the
lever five times to receive one sugar
pellet. Each training session on this
five lever presses to one sugar pellet
fixed ratio lasted until the animal
received at least 50 sugar pellets.
Two 5:1 fixed ratio training sessions
took place.

2.2.3 Experiment 2
Experiment 2 consisted of
three parts. All three parts of this
study were based on the rats’ ability
to press a lever to receive a 45 mg
sugar pellet. Before Part 1 of the
study began, the rats’ rate of lever
pressing for a sugar pellet reward
(on a 5:1 fixed ratio) was assessed
and recorded as a control measure
for lever pressing behavior.
Part 1 of Experiment 2 further
focused on developing an animal
model for PTSD, but used freezing
behavior, rather than burying
behavior or anxiety, as the
predicative factor of PTSD. After
being trained to press the lever in an
operant chamber, the rats were
placed into the operant chamber and
exposed to inescapable, moderate
shocks (shocks of 0.5 second
duration and 1.5 mA intensity)
occurring at 30 second variable
intervals for 10 minutes, as well as a
predator stress, bobcat urine. A
bright light was paired with each
shock. During this session the rats
were still able to press the lever to
receive a sugar pellet (at a 1-to-1
fixed ratio). At 7, 14, and 21 days, the
rate of lever pressing for each rat
from Part 1 of Experiment 2 was
assessed in the presence of the bright
light, to assess the degree of freezing
each rat expressed.
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Part 2 of Experiment 2
followed the same protocol as Part 1
of Experiment 2. However, a 10
mg/kg intraperitoneal injection of
propranolol was given immediately
following the stress exposure period.
The assessment strategy for Part 2 of
Experiment 2 was identical to that of
Part 1 of Experiment 2.

2.4.1. The elevated plus-maze
In Experiment 1, the rats were
assessed on the elevated plus maze
(EPM). The EPM creates a conflict
situation between the exploratory
drive of rodents and their aversion
to open spaces (Pellow et al., 1985).
The maze consists of two open arms
and two closed arms. The maze
forms a “+” with the open arms and
closed arms lying along their
respective axes. The maze was raised
24 inches above the floor. The rat
was placed in the center of the
apparatus facing an open arm and
allowed to explore the maze for 5
minutes under constant observation.
An arm entry was considered when
all four paws crossed from one arm
and into the other. The amount of
time spent in the open arm versus
the amount of time spent in the
closed arm was recorded. The more
time the animal spent in the closed
arm, the higher degree of anxiety the
animal was believed to have. An
image of an EPM is displayed in
Figure 1.
To assess the degree of
anxiety exhibited by the rat, the rats’
anxiety ratios were obtained.

2.3. Chemicals
Propranolol (15 mg/kg) was
dissolved in saline and administered
via intraperitoneal injection.
Controls received an equivalent
volume of 0.9% saline solution in the
same manner, controlling the
potentially stressful effects of an
intraperitoneal injection. The drug or
vehicle solutions were freshly
prepared and injected at the same
time of day in a volume of 1 ml/kg
body weight.
2.4. Behavioral measurements
Over the course of the two
studies, an elevated plus maze and
lever press rate comparisons were
used to assess anxiety and freezing
behavior, which are indicative of
PTSD-like symptoms. All behavioral
measurements were recorded by the
experimenter at the time of
assessment.
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The higher the anxiety ratio, the
greater the amount of anxiety the rat
expresses.
2.4.2. Ball burying behavior
The frequency of ball burying
is predicative of PTSD in an animal
model. Although burying is a rare
behavior in wild rats, it is thought to
represent the symptoms of PTSD
when it follows a stress exposure
period (Mikics et al., 2008). The
animals were exposed to the softflight tennis ball for a 15 minute
period at 7days post stress as well as
28 days post stress. The amount of
time the animal spent burying the
ball, exploring the ball (sniffing,
biting, or grabbing the ball), and the
amount of time spent ignoring the
ball was observed and recorded by a
single examiner.

Figure 1. – Detailed image of an elevated plus maze.

used to assess the rate of lever
pressing post trauma in order to
account for the press rate when the
light was on as well as when the
light was off.

2.4.3. Rate of lever pressing
The two previous methods of
assessment (used in Experiment 1)
did not measure the degree of
freezing which is a hallmark trait of
PTSD in an animal model. In
Experiment 2, the degree of freezing
was assessed by comparing the prestress rate of lever pressing with the
rate of lever pressing 7, 14, and 21
days following the traumatic
experience. A suppression ratio was

The suppression ratio is inversely
proportional to the degree of
suppression. As the suppression
ratio decreases, the amount of
suppression increases.
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The greater the difference in
these measures pre and post stress,
the higher degree of freezing the
animal has had. The control animals
were assessed at the time of stress,
although they themselves were not
stressed, 7, 14, and 21 days after the
stress. This provides an indication of
the reduction of lever pressing over
time.

ratio of .819 ± .241 while the rats who
received the propranolol injection
had a mean anxiety ratio of .692 ±
.344. Some rats received propranolol
and were observed 7 days post
stress; the mean anxiety ratio of this
group was .910 ± .103. Others were
observed 28 days post stress; the
mean anxiety ratio of this group was
.540 ± .375. There was a main effect
of treatment on anxiety, F(1,27) =
4.85, p = .036, ηp2 = .152 (Figure 2).

3. Results

Experiment 1 assessed the
degree of anxiety exhibited by the
rats as well as the degree of avoidant
behavior exhibited by the rat.
The anxiety ratios were
analyzed for effects of stress (stress
or no stress), treatment (immediate
administration of a propranolol
injection or a saline injection), and
time (7 days post trauma or 28 days
post trauma). A univariate ANOVA
revealed that there was no
significant effect of stress on anxiety,
F(1,27) < 1.
However, the treatment
condition did appear to show an
effect. The rats who received the
saline injection had a mean anxiety

1
Anxiety ratio

3.1. Experiment 1 - Effect of stress,
propranolol, and time on anxietylike behavior and ball burying
behavior.

0.8
0.6
0.4
0.2
0
Propranolol
Saline
Control rat
(no stress injected rat at injected rat at
28 days post 28 days post
and no
stress
stress
injection)

Figure 2. – This figure illustrates the mean
anxiety ratios of the control group, saline group,
and propranolol group 28 days after the stress
trial. The difference between the control rats and
the rats who received the stress with no
treatment was insignificant 28 days after the
stress trial. However, the administration of a
propranolol injection following the stress trial
significantly reduced the anxiety ratio expressed
by the rats F(1,27) = 4.85, p = .036.

- 38 -

PROPRANOLOL AND PTSD

Experiment 1 also assessed
ball burying behavior by the rats as a
measure of avoidant behavior. Only
four of 31 rats (28 of which were
stressed) exhibited any degree of ball
burying behavior. There were no
effects of stress (F(1,27) < 1),
treatment (F(1,27) = 2.493, p = .126),
or time (F(1,27) < 1) on ball burying
behavior

Time also had a significant
effect on the rats’ anxiety. The mean
anxiety ratio of rats assessed 7 days
post stress was .910 ± .103. The mean
anxiety ratio of rats assessed 28 days
post stress was .700 ± .306. There was
also a main effect of time on anxiety,
F(1,27) = 8.52, p = .007, ηp2 = .240
(Figure 3).

3.2. Experiment 2 - Effect of
propranolol and time delay until
assessment on post-stress freezing
behavior

Anxiety Ratio

1
0.8
0.6
0.4
0.2
0
Control rat Propranolol Propranolol
(no stress injected rat at injected rat at
7 days post 28 days post
and no
stress
stress
injection)
Figure 3. – This figure focuses on the effectiveness
of propranolol over time. The effect of time on
anxiety ratio is significant in that if causes the
anxiety ratio to increase, even when propranolol
was administered as a treatment, at seven days
post stress but decrease beyond the level of premorbid functioning at 28 days post stress (when
treated with propranolol, F(1,27) = 8.52, p = .007.
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Experiment 2 aimed to
evaluate the rat model of PTSD used
in the present study by assessing
freezing behavior as a result of the
stress induced. In order to initially
test freezing behavior due to the
induced stress, a baseline rate of
lever pressing was observed prestress and then each rat’s post stress
lever press rate was observed 7, 14,
or 21 days after the stress was
administered. A t-test was
conducted on baseline lever press
rate and post stress lever press rate.
The post-test rate of lever pressing
was significantly lower than the
baseline rate of bar pressing
behavior (t(32) = 5.977, p < .001).
Upon establishing that the
animal model of PTSD significantly
affected the rats’ bar press rates, a
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week one is significantly lower than
the mean suppression ratio of rats
observed at week two, p = .004, and
that the mean suppression ratio of
rats observed at week three is
significantly lower than the mean
suppression ratio of rats observed at
week two, p = .001. The suppression
ratios of rats observed at weeks one
and three were not significantly
different.

0.8
0.7
Suppression Ratio

univariate ANOVA was conducted
to determine the effects of the
treatment condition and time
condition on press rate behavior. The
baseline press rate was covaried in
order to eliminate any effects that the
rat’s baseline press rates may have
on the analyses.
Propranolol did not have a
significant effect on lever press rate
as indicated by the rats’ suppression
ratios. The rats that were given a
saline injection had a mean
suppression ratio of .545 ± .110. The
rats given a propranolol injection
had a mean suppression ratio of .590
± .121. The effect of propranolol on
lever press rate was insignificant,
F(2,23) = 1.99, p = .158, ηp2 = .148.
The effect of time did
significantly affect the rats’ lever
press rate as indicated by their
suppression ratios. The rats’ mean
suppression ratio when observed 7
days after stress was .529 ± .101. The
rats’ mean suppression ratio when
observed 14 days after stress was
.642 ± .107. The rats’ mean
suppression ratio when observed 21
days after stress was .495 ± .088. The
amount of time elapsed between
stress and observation was
significant, F(2,23) = , p = .002, ηp2 =
.409 (Figure 4).
A pairwise comparison of the
time data indicates that the mean
suppression ratio of rats observed at

0.6
0.5
0.4
0.3
0.2
0.1
0
7 days

14 days

21 days

Number of days after stress exposure
Figure 4. – This figure focuses on the effect of time
on suppression ratio as a measure of freezing
behavior, F(1,23) = 7.962, p = .002. As time
increased since the stressor, the degree of
suppression measured had increased at the 14 day
mark but then decreased at the 21 day mark.
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(2010) claims that burying behavior
is a rare behavior in wild rats.
Burying behavior would have
suggested that the rat wanted to flee
the object associated with the stress
experience. If the stress procedure
was not sound, the rats may have
paired the memory of the stress
experience with the operant chamber
rather than the novel object,
explaining why burying behavior
did not occur. Another plausible
explanation is that the rats simply
did not know how to bury.
The rats may not have
exhibited changes in anxiety ratios
because they were already anxious.
The continual handling,
transportation, and movement of the
laboratory rats, in addition to their
unnatural housing environment,
may lead the animals to be in a
constant state of anxiety. Data
presented in Experiment 1 supports
both of these theories.
In order to confirm one of
these theories, further
experimentation must be completed.
First, it would be useful to use the
current procedure and collect the
same data again, but to also collect
data at 7 days post-stress for the
anxiety ratio of rats that were given a
saline injection. It would also be
beneficial to calculate the anxiety
ratios and observe the burying
behavior of rats (in the same control

4. Discussion
4.1. Discussion of results found in
Experiment 1
The main findings from
experiment 1 were threefold: 1) there
is no effect of the stressful experience
used in this experiment on the rats’
anxiety ratios, 2) propranolol did
effectively reduce the rats’ amount of
anxiety 28 days after the stress
experience, and 3) the time course
data suggests that the rats’ anxiety
ratio increased at 7 days post-stress
but had normalized back to the
control measure by 28 days post
stress.
The finding that the stressful
experience does not affect the rats’
levels of anxiety 28 days post trauma
(as indicated by the EPM data)
suggests that either the stress
experience used to elicit PTSD-like
behavior did not significantly affect
the rats’ level of anxiety or
potentially that laboratory rats are in
a perpetual state of anxiety and
stress. An argument can be made
that the present stress protocol did
not alter anxiety levels or elicit
PTSD-like symptoms because of the
procedure of the present study.
Support for this claim comes from
the lack of burying behavior by the
rats in response to the stress and
treatment. However, Langevin et al.
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and experimental groups) when
stressed with a different stress
protocol. A time dependent
sensitization stress paradigm using
restraint and forced swimming have
also been effective in eliciting PTSD
in an animal model (Harvey et al.,
2006).
Another significant finding is
that propranolol effectively reduces
rats’ level of anxiety 28 days poststress. This finding supports that
propraonol effectively reduces
anxiety (Pitman et al., 2002; Vaiva et
al., 2003). The claim that the stress
experience does alter the rats’ level
of anxiety because it causes the rat to
lose all recollection of emotions
associated with the experience seems
to be supported.
Propranolol does not show
this same effect 7 days post-stress. At
7 days post-stress, the mean anxiety
ratio is increased from the control
measure (the anxiety ratio of nonstressed rats) to 0.910. Although the
anxiety ratio has increased,
propranolol was not proven effective
at 7 days post stress for decreasing
the rats’ anxiety ratio due to
insufficient information. The anxiety
ratio of saline injected rats 7 days
post stress was not observed. Thus,
propranolol may have an effect on
rats’ anxiety ratios one week after
stress, but if so, the effect is not great
because the anxiety ratio still

increased significantly from the
control. Propranolol’s inability to
reduce anxiety 7 day post trauma
supports Cohen et al.’s (2011) claims
that propranolol is ineffective in
preventing PTSD.
The data from Experiment 1
also suggests that there is a time
course associated with the
effectiveness of propranolol or the
presentation of PTSD-like
symptoms. The data concerning time
course shows that propranolol has
greater effectiveness at 28 days, than
at 7 days, post stress. Therefore, the
data indirectly suggests that the rats’
anxiety level increases 7 days post
stress, but then normalizes again by
28 days post stress. The rats’ mean
anxiety ratio increased at 7 days post
stress despite the propranolol
treatment, and then normalized at 28
days post stress. These findings
support a time course to be
associated with PTSD symptoms,
and that PTSD symptoms do not
necessarily develop immediately
following the trauma.
4.2. Discussion of results found in
Experiment 1
Experiment 2 yielded two
findings worth further discussion: 1)
propranolol did not significantly
affect freezing behavior and 2) time
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after stress influences the degree of
freezing behavior in rats.
When propranolol treated
rats’ freezing behavior (as indicated
by the suppression ratio of lever
pressing with the light on) was
compared to the saline treated rats’
freezing behavior, there was not a
significant effect. This may be
explained in two ways. One
explanation is that the propranolol
administration did not effectively
treat the symptoms elicited by the
stress experience. For instance, one
dose of propranolol immediately
following the stress may not have a
great enough effect on the rat. In
human trials, a series of doses must
be administered to see an effect on
PTSD symptoms (Vaiva et al., 2003).
Likewise, the one dose of 15mg/kg
may not have significantly affected
the rats’ behaviors or symptoms. The
other issue may have arisen in the
process of pairing the stressful
experience with the novel object. It
may be that the rat did not pair the
stressful event with the novel object,
but the operant chamber itself.
The data collected from
Experiment 2, like Experiment 1’s
data, suggest a time course for
PTSD-like symptoms. The mean
suppression ratio of rats observed at
14 days post stress were greater than
the suppression ratios of the rats
observed at 7 days post stress, but

the mean suppression ratio of rats
observed 21 days after the stress
were lower than the suppression
ratios measured at 7 days post stress.
Thus, the degree of suppression
began to increase again between 14
and 21 days post stress. Using
freezing behavior as the determining
factor of PTSD in an animal model,
an animal model of PTSD may be
developing by 21 days post stress,
but does not begin to develop before.
This data supports the data from
Experiment 1, indicating that PTSD
symptoms do not develop
immediately after the stress.

5. General Discussion
Based on the results of the
two experiments conducted in this
study, neither of the two hypotheses
presented at the beginning of the
study were supported. The stress
experience did not affect the rats’
ball burying behavior or anxiety
level 28 days post trauma, and
although propranolol did reduce
anxiety, it did not significantly affect
ball burying or freezing behaviors,
which were also used as measures
for PTSD symptoms.
Despite rejection of the
hypotheses, the present study does
prove useful for future PTSD
research. The pre and post stress
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lever press rates and suppression
ratios suggest that an animal version
of PTSD was elicited in the rats.
Likewise, if future research indicates
that the lack of anxiety level
increases at 7 days post stress, then it
may be concluded that the stressful
experience did in fact resemble a
trauma that could elicit PTSD-like
symptoms. The present protocol for
eliciting PTSD-like symptoms may
be slightly altered to truly determine
if the present stress protocol does
produce PTSD-like symptoms in rats
and if propranolol effectively
prevents such symptoms.
Additionally, this data indicates that
propranolol is effective for treating
anxiety. The data also provides
support for a delayed development
of PTSD symptoms.
The findings from this study
suggest that PTSD symptoms do not
develop immediately following the
trauma, but take time to develop. In
this rat model, PTSD symptoms do
not begin to exhibit themselves until
the third week after the stress
experience. Evidently, posttraumatic
stress disorder does exhibit itself in
different patterns. Different
individuals may respond to a single
trauma very differently. Individuals
may also differ in their presentation
of the PTSD symptoms. Symptoms
may appear immediately after the
trauma or months or years later

(Cantor, 2005). This study indicates
that the time course for a rat to
exhibit PTSD-like symptoms is
approximately 3 weeks. Hopefully
this study provides insight to future
studies regarding the testing of
PTSD and potential treatments of the
disorder in the animal model.
In conclusion, despite finding
no significance of the effects of
propranolol, this study was
successful in unexpected respects
and contributes to the neuroscience
and PSTD research fields.
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The Afterword:
One treatment, many implications, more questions…

“Everybody says we're all so different
But everybody knows we're all the same
We're all trying to find a pill to numb the pain
Something's got to change”
~ Josh Wilson, Something’s Got to Change
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The effects of propranolol, a non-selective β-adrenergic antagonist, on rat behavior
in an animal model of posttraumatic stress disorder is the foundation for this thesis
and provides new research to the field of neuroscience and PTSD literature.
Through this study, the effects of propranolol on a rat version of PTSD, which
was influenced through a stress protocol adapted from previous fear
conditioning and PTSD studies, were tested. Propranolol did not effectively
decrease all PTSD symptoms in this study, as I had expected, but I did find that a
single 15 mg/kg dose of propranolol administered immediately after stress
significantly reduced the rats’ freezing behavior 28 days after administration. I
also found that the PTSD-like symptoms that the rats experienced had a distinct
time course. Furthermore, this research has helped me generate more ideas for
potential studies concerning the development of pharmacological treatments for
PTSD. Ultimately, this study led me to insights regarding PTSD, propranolol,
and PTSD research.
Although the research completed, and presented in this thesis led to
positive, yet unexpected, results, I realize that many ethical questions arise from
this research as well. The present study did not support the hypotheses stated at
the onset of the experiments or lead to any truly extraordinary findings in
regards to a treatment for posttraumatic stress disorder (PTSD). It did however,
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subject animals to psychological stress. Although researchers design experiments
to yield results consistent with their hypotheses, this does not always occur. My
study is not the only study that has ever failed to support its hypotheses, and it
definitely will not be the last. The stresses of experimentation, however, are
present across all research and are consistently impressed upon the research
subjects or participants. Thus, the question arises, should scientific research
which causes any element of harm be tolerated? This complex question tends to
polarize people. The views concerning scientific research, and each of its
subtypes, range from fully condemning research to entirely supporting it as the
most beneficial tool for furthering knowledge about the world. The use of
animals as research subjects is a clear example of this polarization, and is another
ethical concern brought about by my study. Why should one complete research
on animals rather than humans? Is an animal’s life less valuable than the life of a
person?
In addition to the questions directly surrounding my research, questions
surround the search for a treatment for PTSD. The overarching question is
whether or not individuals suffering from PTSD should be provided a
pharmacological treatment to prevent or reduce their symptoms. The initial
response to this question may seem simple, but when the side effects of the
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treatment(s) are taken into consideration, the answer becomes more convoluted.
To treat PTSD, the memory of the trauma or the relationship one has with that
memory must be treated. Most pharmacological treatments aim either to
eliminate the memory completely or to blunt the emotions associated with the
memory. Ethical questions arise concerning the value of one’s memory, the value
of one’s emotions. After exploring these questions, one must also question how a
pharmacological treatment may be implemented and the greater effects of a
PTSD treatment on society.
Questions like these often go overlooked in the scientific community, but
regardless, it is important to investigate such ethical questions. Although it
would be an amazing scientific feat to discover a treatment, one cannot ignore
the ethical questions surrounding PTSD treatment research simply because of the
scientific interest. It is also important to think about each ethical question
individually, and not simply agree with the common answers to the ethical
questions.
Before I begin exploring the overarching question of whether or not a
treatment of PTSD should be made available, I must address the ethical concerns
of scientific research. In the following section I will outline the current stance of
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the scientific community on scientific research that uses humans as research
participants and that uses animals as research subjects.

I.

Current views of scientific research using humans as research
participants and animals as research subjects
The general view of the scientific community is that scientific research is

justifiable with the participant consent to the investigation as long as no harm is
deliberately imparted upon the participant. Immanuel Kant states that “a human
being, and in general every rational being, does exist as an end in himself, not
merely as a means to be used by this or that will as it pleases” (Sandel, 2007). I
completely agree with this Kantian philosophy, and so does the scientific
community. Although scientific research may not always produce the results that
the researcher(s) believed it would, the benefits of scientific research will
continue to outweigh the costs as long as the participants’ individual rights are
respected and the ethical guidelines outlined above are upheld. If any form of
research were proposed in which people were forced to participate in a study or
the study infringed upon the participant’s rights, the research would not be
allowed to occur. Each person should be treated equally, and guaranteed his or
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her rights. In order to guarantee that each person is treated as an end in himself,
ethical principles have been developed to guide scientific research.
Three primary principles must be upheld in scientific research that uses
humans as research participants. The first principle is respect for persons. This
principle emphasizes the inherent dignity and worth of each person. The
principle requires science to respect individuals and their autonomy; it means
not treating people simply as a means to an end, but encouraging their right to
self-determination and the right to make choices, to hold views, and to take
actions based on personal values and beliefs. Based on this principle, one should
always “act in such a way that you treat humanity…always at the same time as
an end, never merely as a means” (Sandel, 2007). The respect for persons principle
emphasizes the responsibility individuals have for their own lives. The second
principle has to do with maximizing benefits while minimizing harms. To maximize
benefits one would help others and act in their best interests while creating the
greatest wealth of new knowledge. Meanwhile, minimizing harms obligates
others to minimize the amount of harm intentionally inflicted on the participant.
The third principle relates to giving each person his or her due. This dictates that
each person should qualify for equal treatment because each person is equally
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human. All resources, risks, and costs should be equally available (NWABR,
1999).
In addition to these three principles, more pointed guidelines must also be
followed. The American Psychological Association has outlined ten general
principles governing the conduct of research with human participants. Among
these principles are: gaining institutional approval for the research at hand (if
necessary), gaining informed consent to research from the research subject,
gaining informed consent for recording voices and images during research,
ensuring protection of subordinate research participants (students, patients,
clients, etc.) from adverse consequences of declining or withdrawing from
participation, dispensing information only with informed consent and for a
legitimate reason, offering reasonable inducements for research participation,
minimizing deception in research, providing a debriefing session for the research
participant(s), and caring for all animals involved in research in a humane
manner (Elmes, Kantowitz, & Roediger III, 2006). Although these ethical
guidelines are expansive, they are necessary to allow for the pursuit of
knowledge through scientific research in an ethical manner. These principles are
intended to protect the welfare of research participants, and they can be
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summarized by noting that the experimenter has an obligation to minimize harm
to the participant while treating him or her with respect and seeking to maximize
the benefits that may be gained from the research.
As long as the aforementioned ethical guidelines are upheld, scientific
research and the resulting knowledge is not only ethical, but it is necessary.
Science is the only avenue of learning for certain disorders. For instance, the
etiology and treatment of psychological disorders cannot be understood without
studying the individuals with the disorder or inducing such a disorder in an
animal subject or human participant in order to test potential treatments. Even
though some research has already been conducted on PTSD, very little is known
about the disorder. While it is known that the hypothalamic-pituitary-adrenal
(HPA axis), the hippocampus, the amygdala, the prefrontal cortex, as well as six
neurotransmitters and neuropeptides are implicated in PTSD, it is not clear
which abnormalities within the CNS actually lead to the development of PTSD
symptoms. Thus, there is a tremendous need for more research on the
neurological abnormalities that underlie PTSD. Perhaps if a person can
understand the neurochemistry of PTSD he or she can find a treatment for the
disorder. Without the ability to complete scientific research, treatments for
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psychological disorders like PTSD would never be developed. As long as
person’s rights are respected, scientific research that uses humans as participants
is encouraged.
The scientific community does not hold quite as stringent views on animal
research. Although a better understanding of the neurobiology of PTSD may be
obtained through the dissection of human brains that have experienced PTSD,
and eliciting PTSD in humans rather than animals would lead to understand
PTSD as it affects the human brain, these research techniques violate the ethical
guidelines of human research. However, the scientific community is comfortable
with using these same research techniques in animal models.
Animals may be used for certain types of research that humans cannot
because of the need for better scientific understanding of diseases and disorders
as well as the logic that animals do not have the same moral rights as humans.
Every effort should be made to do what is best for the individual and society as a
whole. The pursuit of a treatment for PTSD, and any other psychological
disorder, would allow for the individual to return to his or her premorbid level
of functioning and a degree of suffering would be removed from the world.
Animal research may be a way to obtain this objective. Cohen (1986) explains
that animals are incapable of moral agency and therefore lack moral rights.
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Rights only arise among beings that can actually make moral claims against one
another. Animals do not have the capability of moral judgment, and therefore,
do not have any rights (Cohen, 1986). Based on the knowledge to be gained from
animal research coupled with the belief that animals do not have moral agency,
the scientific community believes that animals should be appropriately used to
advance biomedical research (Mappes & Degrazia, 2006). The scientific
community allows animal research in the pursuit of furthering scientific
knowledge.
Although researchers are able to use animals as research subjects, they are
not free to treat animals in any way that they see fit. Animals certainly suffer,
and should not be made to suffer needlessly. It is accepted that animals do not
have a moral status comparable to that of humans. This is evident through our
willingness to set a mouse trap or prepare a boiling pot of water for a lobster
dinner. However, it is also generally agreed upon that animals have certain
liberties. The biomedical and animal protection communities both agree on the
following: the use of animals in biomedical research raises ethical questions,
sentient animals deserve moral protection, animals are capable of having a wide
variety of aversive mental states (including pain, distress, and suffering), and
animals’ overall well-being deserves protection (Hettinger, 1989). On the other
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hand, these communities also agree that promoting human health is extremely
important and that there are some morally significant differences between
humans and other animals (Hettinger, 1989). From these beliefs, it is accepted
that animal research is justified only when the ethical guidelines for animal
research are followed.
The Council for International Organizations of Medical Sciences (CIOMS)
assumes that the moral status of animals does not preclude the need for animal
use in research. At the same time, CIOMS asserts that researchers have certain
responsibilities to minimize the animal’s pain, distress, and discomfort and must
use alternatives to animal research whenever possible (Mappes & Degrazia,
2006). In accordance with the CIOMS’s view, Bear et al. (2007) gives three main
responsibilities that neuroscientists must uphold when conducting neuroscience
research with animal subjects.
1. Animals should only be used for experiments that promise to
increase knowledge of human systems or diseases affecting those
systems. In other words, the benefits of the experiment must
outweigh the costs. If animals must be sacrificed or harmed, the
experiment must be in the pursuit of greater knowledge.
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2. All possible steps must be taken to minimize any pain or distress
the animal may experience.
3. The researcher must consider all possible alternatives to the use of
animals as research subjects.
If these three responsibilities are upheld, animals are acceptable research
subjects. The general assumption among the research community is that it is
unethical to use animals profusely or for commonplace research, but that “it is
immoral not to wisely use all the resources that nature has provided, including
animals, to gain an understanding of how the brain functions in health and
disease” (Bear et al., 2007). Animals may, and should, be ethically used in
scientific research so long as such research eventually leads to an overall greater
quality of life.
In summary, scientific research is not only accepted but also encouraged
as long as the previously outlined ethical guidelines are upheld for human
research participants and animal research subjects. For the research that cannot
be completed with human participants, animals are the avenue in which this
knowledge may be acquired. Although it would be ideal to inflict no harm in the
pursuit of knowledge, this is not always possible. Every benefit has a cost
- 58 -

PROPRANOLOL AND PTSD

associated with it. The scientific community has decided that the benefit of
developing cures for various diseases and disorders outweighs the cost of
animals’ lives. However, looking at the situation in another light, animals used
for all types of biomedical research is less than 1% of the number of animals
killed for food in the United States alone (Bear, Connors, & Paradiso, 2007). By
using the ethical guidelines for animal research, animal lives are considered and
animals are only used as research subjects if absolutely necessary. In scientific
research, limited amounts of animal harm are accepted in exchange for a
potential increase of knowledge.

The ethical concerns centered on human and animal research are fairly
common and have been given far greater attention in other works. I have chosen
not to delve into the ethical concerns of scientific research because of more
pointed ethical questions regarding the overarching goal of this thesis, to find a
treatment for PTSD.
Before I move into other ethical questions associated with attempts to find
a treatment for PTSD, it is important to note that all ethical guidelines for animal
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research were upheld in the study I completed. My study was looking to gain a
better understanding of the neurochemistry of PTSD and to test propranolol as
an experimental treatment for PTSD symptoms in rats. Both of these goals were
accomplished, and the research that I completed would not meet the ethical
guidelines to test humans. Also in accordance with the responsibilities held by
the researcher, I did my best to minimize any pain or distress the animals may
experience. The animals were appropriately nourished and housed, and I did not
subject any animals to any threatening experiences outside of the experimental
procedure. Before beginning my experiment, I explored all possible alternatives
to the use of animals in my study. Given the nature of the topic and the focus of
my study, I was led to use animals in my study, but did not violate any of the
aforementioned ethical criteria for conducting research using animals as research
subjects.
My study and overall thesis topic sparks questions surrounding the ethics
of treating PTSD as well as those concerning animal research. On first glance, it
appears justifiable for an individual suffering from PTSD to want his or her
premorbid quality of life, meaning the symptoms from PTSD should be treated.
If a person had a broken leg, he or she would have that leg casted, set back in
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place, and ultimately corrected. The decision to treat mental injuries, especially
PTSD, is not quite that simple. The main side effect of prospective
pharmacological PTSD treatments is either memory loss or the loss of the
emotional connection to the traumatic memory (Cukor, Spitalnick, Difede, Rizzo,
& Rothbaum, 2009). The value of one’s memories and emotions are terribly
important however. A person is only who he or she is because of his or her
previous experiences, the memories of those experiences, and how he or she feels
about those experiences. Altering or fixing one’s mental illness by means of
memory erasure is quite different than fixing a physical injury because mental
abilities create the personal identity of the person affected by the injury. Due to
the value of one’s memories and emotions, the search for a PTSD treatment may
be complicated by whether or not a person is willing to forget one of his or her
life’s most influential experiences. In other words, if one’s memory of, or the
emotional connection to, the experience must go, is it still best for the PTSD
victim to be pharmacologically treated? Conversely, is there a value in enduring
and working though suffering, via therapy options, to alter one’s attitude about
the trauma and overcome one’s symptoms without taking a drug?
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If it is decided that it is best to pharmacologically treat the patient, another
question is raised. Who do you treat and when? In addition to memory loss,
many of these drugs and treatment strategies must be administered either before
or immediately following the trauma. If a drug must be administered before or
immediately following the trauma, how does one choose who does and does not
receive the treatment? What scenarios would qualify a person for this type of
preventative treatment? If a drug were to be administered post-trauma, a person
would need to be able to give informed consent, which could present another
issue with administration. After a traumatic experience, a person may not be in
the state of mind necessary to give informed consent to the physicians. Although
it seems simple at first glance, there are many questions that must be answered
and ethical concerns that must be explored before a treatment for PTSD may be
brought to the public.
The first question to concentrate on is the cost of a treatment for PTSD and
the potential value of suffering. In the study that I completed, I did not see an
effect of propranolol on all PTSD symptoms. Although this research did not
support the hypothesis I set out to address, I am not entirely certain that this
failure to find a consistent working treatment for PTSD disadvantages PTSD
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victims or society. Although it may be crystal clear to many people that PTSD
victims need a drug rather than a therapy, I am not certain that is the case. Before
I proceed further with this line of thought, I must say that I do not have a
personal connection to anyone with PTSD, and I am not attempting to speak as if
I do have such a connection. Clearly, the types of traumas that dispose an
individual to the suffering characterized by PTSD are horrific. I also can attempt
to understand the difficulties that a PTSD victim suffers on a daily basis. Yet, I
am uncertain that a pharmacological treatment for the disorder is the correct
answer to the problem.
The most promising treatments for the 5.2 million Americans suffering
from PTSD are memory attenuating drugs. These drugs, one of which is
propranolol, have shown limited evidence that PTSD symptoms can be reduced
due to the numbing of emotions involved with the memory (Henry, Fishman, &
Youngner, 2007). However there is also some concern that such drugs may lead
to complete memory loss for a period of time (President’s Council on Bioethics,
2003). As a result, the value of emotions and memories has been brought into the
discussion of PTSD treatment. If an individual loses his or her emotional
connections to a memory or loses the memory completely, there may be legal

- 63 -

PROPRANOLOL AND PTSD

implications. In addition to these topics, it is important to consider the lessons an
individual learns as a result of a trauma and how these lessons further
complicate whether or not one’s memories should be altered in an attempt to
treat PTSD symptoms.
It is important to consider the moral costs that may accompany a
pharmacological treatment for PTSD. A PTSD-eliminating drug has many
repercussions for the victim concerning life after the trauma. The opposition for
pharmacologically treating PTSD leads me to question how an effort to help a
PTSD victim may transform into harming the individual and, in turn, society by
the removal of that individual’s connection to the experience. If every victim of a
trauma were to alter his or her memory of the event, it the overall impression of
the trauma would be altered as well. In order to answer this question, I believe
one must explore the value of suffering while remaining conscious to the fact
that 5.2 million Americans are currently suffering from an event that has already
come and gone, but still remaining present in their uncontrollable memory.
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II.

What is the value of suffering?

Before attempting to find value in suffering, it is necessary to establish an
understanding of what I mean by suffering. Although a person may be said to
suffer a broken arm or a sprained ankle, physical pain is not typically what
someone is referring to when he or she says that there is suffering all over the
world. There is a difference between being hurt and suffering. A physical pain
may hurt, but for suffering to result from an experience a psychological pain
must exist as well. Physical hurt and suffering are connected, but separate
phenomena. As I use the term, suffering does not reference physical pain in itself,
but psychological traumas that result from biological malfunctions within the
brain. Suffering is a recently orphaned child whose parents were slaughtered
during a robbery. It is the pain of the people affected by genocide and a
wounded veteran trying to forget the travesties of war. Suffering also ensues
after the loss of a loved one or the permanent loss of one’s physical capabilities.
Although one may physically see the sorrow and distress brought on by the
suffering, suffering itself resides within the mind. Suffering results from feelings
of depletion, loss of meaningfulness, and lack of identity. Although these
examples may detail a physical pain, they also deal with a certain type of
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psychological hardship. The newly orphaned child is forced to deal with feelings
of loneliness, helplessness, and abandonment. Likewise, a population affected by
genocide must deal with thoughts of powerlessness and the war veteran must
overcome the evils witnessed in war. Losing a loved one or a person’s ability to
function completely alters the life of the individual, and he or she is forced to
recreate his or her identity and meaning in life. In generalized, more abstract
terms, suffering is the form that a memory takes when it is charged with negative
emotion.
All people suffer to some degree, but the type of suffering that is endured
by PTSD victims is the result of biological malfunctions that cause a single
moment in time to be relived unconsciously and uncontrollably. A desire of the
body is to maintain equilibrium. The body attempts to avoid the emotional
charging of negative emotions and minimize suffering. The human mind
attempts to maintain equilibrium between memory and oblivion and rejects
irrelevant or disruptive memories (Evers, 2007). The extensive amounts of stress
hormones released at the time of a traumatic event lead to an inability to reject
the memory, and subsequently give rise to a powerful memory which
continually replays in the individual’s head (Heim & Nemeroff, 2009). At this
point, PTSD develops and suffering ensues. PTSD is a severe form of suffering,
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and due to this severity, the initial response is that the suffering must be treated
in a way that returns the victim to his or her pre-morbid style of living. After all,
since PTSD is detrimental and results from biological malfunctions, a drug
should be developed to correct those malfunctions, right?
The degree of dysfunction that suffering can cause for those suffering
from its most severe forms makes it important to attempt to find value in
suffering. Suffering causes a great deal of psychological pain and in many cases,
physical pain as well. For instance, consider an example of human suffering that
Fyodor Dostoyevsky outlines through the words of Ivan in Book V of The
Brothers Karamazov:
Imagine a trembling mother with her baby in her arms, a circle of
invading Turks around her… pet the baby, laugh to make it laugh. They
succeed; the baby laughs. At that moment, a Turk points a pistol four
inches from the baby’s face. The baby laughs with glee, holds out its little
hands to the pistol, and he pulls the trigger in the baby’s face and blows
out its brains (1880).
The imagery of this scene evokes sorrow for the naïve child, but attempt to
imagine the heart-break that the mother must feel and the subsequent suffering
that will surely ensue. Furthermore, attempt to imagine living with that memory
constantly replaying in your mind for the rest of your life. These situations
support the desire to eliminate suffering. A single case of PTSD and the
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experiences leading up to this psychological trauma cause any observer to ask:
who deserves this? No person deserves to suffer in this manner, but suffering
remains a part of daily life due to the free will of humankind. With free will, evil
is a part of the human condition, and due to this evil suffering enters into the
world. Since evil continues to exist, the goal is to overcome suffering and to find
value in life in the midst of suffering. Alone there is no value in suffering. No
person can honestly claim that there is value in a mother watching her child be
executed in front of her eyes. However, there is value in the process of
overcoming suffering by addressing the traumatic experience and attempting to
move forward to find meaning as a result of that experience.
While free will allows suffering to enter into the world, it also allows for
pleasure, love, and positivity. In Man’s Search for Meaning, Dr. Viktor Frankl
exhibits how free will can lead to drastically different outcomes. Frankl states,
“Man is that being who invented the gas chambers of Aushwitz; however, he is
also that being who entered those gas chambers upright, with the Lord’s Prayer
or the Shema Yisrael on his lips” (1985, p.157). Free will allows for suffering, but
it also provides an individual the option of offering love to a fallen war veteran
or a woman who was not given a choice. Free will allows an individual to show
love to those who are suffering and to have a voice in advocating a treatment for
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disorders such as PTSD. Through free will a person has the choice to react to
each experience as he or she wishes. With the freedom of choice comes the
freedom of opportunity, both good and bad. Freedom may lead to suffering, but
it also provides the opportunity to rush toward meaning.
Through free will, a person is provided the opportunity to react to each
scenario in the way that he or she chooses. There are two methods by which a
victim may choose to move past the reliving of traumatic memories. One way is
to mitigate suffering with a pharmacological treatment, such as propranolol.
Through such a treatment, a person may never develop the traumatic memories
that perpetuate suffering. Another option is to work through one’s suffering
rather than taking a drug, and realizing that the trauma is now in the past, that
each day is a brand new day, and that there is meaning in the life that still lies
ahead. In other words, one may work to overcome his or her suffering to find
meaning.
Overcoming suffering without a treatment is tough but not impossible.
What does it mean to overcome suffering? Overcoming suffering means
recognizing that a trauma occurred, understanding that there is suffering
attached to that trauma, and realizing that one can reduce his or her suffering by
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changing his or her relationship with the traumatic experience. While this is
easier said than done, it can be realized. No trauma victim is in this process
alone, and needs to utilize his or her support system to help get him or her
through this tough time. In addition to family support, individuals may look for
therapeutic help.
The three most common therapy treatment methods for PTSD are
cognitive behavior therapy, eye movement desensitization and reprocessing
(EMDR), and stress management (Ponniah & Hollon, 2009). Trauma-focused
cognitive behavior therapy involves repeated exposure to the traumatic memory
through cognitive methods and then progressively changing the individual’s
thought processes and behaviors towards the trauma. EMDR utilizes dual
attention tasks to help the patient process the traumatic event. EMDR involves
the patient focusing on negative trauma-related memories while engaging in a
task involving some form of bilateral stimulation, such as eye movements, until
distress has decreased and belief in more positive trauma-related thoughts has
increased. Stress management does not focus on the trauma, but involves the
patient’s learning skills to help manage anxiety. Such skills consist of slow,
abdominal breathing, relaxation techniques, learning to use positive statements
and self-talk strategies, distraction techniques, and assertiveness training.
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Therapies such as these help trauma victims manage and eventually overcome
their suffering. Once suffering is overcome, meaning may be found in the
individual’s renewed appreciation for life absent of suffering.
Despite the intentions of these therapeutic treatments, the efficacy of these
therapies is not ideal. Although these therapies prove helpful for some patients
suffering from PTSD, 30% of patients who develop PTSD will still be suffering
from treatment ten years following the trauma (Langevin, De Salles, Kosoyan, &
Krahl, 2010, p. 1241). These individuals may not have received therapy or
followed through with their therapy, but regardless, 30% is a large number of
PTSD victims with chronic symptoms. For this reason, current research
surrounding prevention strategies for PTSD has concentrated its efforts on
pharmacological treatments.
The goal of a preventative pharmacological treatment is to alter one’s
memories, effectively inhibiting PTSD symptoms. Researchers and physicians are
looking at experimental drugs that may numb the emotions associated with a
patient’s memories or perhaps eliminate recollection of the traumatic memory
entirely. It is not practical to erase a patient’s past memories. However,
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eliminating a group of memories that relate to a tormenting period of a patient’s
life is not out of the question.
Research has progressed in identifying potential drugs that may be
utilized as preventative PTSD treatments. Over the past decade, corticosteroids,
beta-adrenergic antagonists (propranolol), and opiate analgesics (morphine)
have been shown to reduce hormonally enhanced memories and fear
conditioning (Cohen et al., 2010). Other drugs such as D-cycloserine, a NMDA
receptor agonist, Ketamine, an NMDA receptor antagonist, Praosin, an alpha-1
adrenergic receptor antagonist, and Ecstacy have all shown promise in
selectively altering individual’s memories and reducing PTSD symptom severity.
The discovery of a drug that would allow people who experience a
traumatic event to continue on with their lives rather than develop PTSD would
be a great finding. With such a treatment, there may be a way for the mother,
who saw her baby executed at point blank, to have peace of mind. Although this
does not completely eliminate traumatic events, it does eliminate the day to day
struggles that a person may face as a result of such events. If the mother does not
remember seeing her baby taken from her, she is much less likely to suffer. In
much the same way, a war veteran with PTSD may finally be able to sleep
through the night without revisiting Vietnam. To rid an individual of his or her
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suffering is to give the individual a renewed quality of life. Clearly, such a
treatment has great potential for improving the lives of many.
The benefits of eliminating suffering are evident, but there are also
arguments warning against such action. Whether one’s memories are
excruciating, glorious, or both, experience is what shapes who an individual
becomes and how that individual derives meaning from life. Suffering is only
known as a result of the knowledge and memories of the way things were before
a certain traumatic event. Each individual is who he or she is, at this moment,
because of his or her memories of the experiences that he or she has encountered.
Memory has a tremendous value regarding who we are as human beings.
In The Use and Abuse of History, Nietzsche speaks of history, or memory, and
proceeds to pose a question. Nietzsche asks if you would rather live as a cow
simply living in the moment feeding on hay or as you are with all your thoughts,
worries, and concerns. According to Nietzsche, man envies the “beast’s
happiness,” but would never change places with the beast (1874). Nietzsche
suggests that memories are worth the cost of unhappiness because there is value
in knowledge of the past, and this knowledge adds depth to each person.
A major criticism of a possible PTSD treatment is that it may eliminate a
crucial memory to the individual’s life. Nietzsche is also quick to point out that
- 73 -

PROPRANOLOL AND PTSD

forgetting helps make a person who he or she is along with memories. Some
things in life must not be remembered. The true question is which memories
should be remembered and which ones forgotten. It may be argued that if a
memory is going to be forgotten, why not a painful memory? Yet it may be
argued just as strongly that a traumatic memory affects an individual the way it
does for a greater reason. Should an individual eliminate a memory that will
have a truly profound impact on his or her life, even if there may be potential
suffering as a result of that memory? For the majority of PTSD victims, I believe
that the experience should be worked through because meaning can be derived
from the experience. However, if a person believes that he or she cannot live with
his or her suffering, it may be best for that person to eliminate the traumatic
memory. There is no value in suffering alone. The value associated with
suffering is found through the transformation of one’s outlook on life and the
discovery of meaning.
The other mechanism through which a PTSD treatment may work is by
numbing the emotional impacts of a memory. Opposition to this approach
surrounds the idea that one’s emotions are intimately linked to his or her outlook
on the world. Hurley (2007) explains that emotions are often seen as an
individual’s understanding of his or her circumstances. For instance, a person
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may be afraid because there is an immediate threat. Additionally, emotions serve
evaluative purposes. Emotions show the values that a person holds, but they are
also able to change based on the circumstances of the situation. For example, a
mother may show compassion to her son struggling with PTSD after returning
home from war. Emotions serve vital purposes in human lives.
The elimination of one memory’s emotional associations would not
contribute to personal change in the same way as the erasing of an entire
memory would, but it would change the relationship to a traumatic event. For
example, if a rape victim was treated with propranolol immediately following
being raped, and did not have any emotional connection to the incident, she
might not be able to realize fully the horror of the event that happened to her.
She may know that rape is a terrible act because she has been told so, but she
may not know this personally due to her lack of a negative emotional experience
to being raped. If she was raped and did not have an adverse reaction to the
event, the general opinion that rape is bad may be challenged by the individual’s
lack of emotions related to the experience. The loss of one emotional connection
may not greatly influence society, but the cumulative loss of all the emotional
connections of all the traumatic experiences of all victims with PTSD would have
a profound effect on society. Using the same example, if no rape victim had a
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negative emotional connection to the event because each rape victim was given a
memory altering drug to repress the effects of the sexual event, rape may not be
viewed as such an evil act. Emotions play a major role in humans’ lives and are
as crucial as memories to an individual’s identity.
The answer to overcoming suffering does not lie in eliminating the
memory of the trauma or preventing a memory from developing, but in deriving
meaning from the events that have occurred and altering one’s relationship with
the traumatic event. Suffering is the form that a memory takes when it is
extremely charged with negative emotion. One’s memories play a huge role in
suffering. It is impossible to eliminate or even lessen suffering unless one is
willing to alter the relationship one has to his or her memories. It is one’s
memory that provides a reference for what does and does not cause suffering.
Memories of good and bad times, and feelings of disappointment, anger,
suffering, or any other emotion are only understood because of previous
experiences. In addition to providing a reference point, memory provides the
narrative that continually influences suffering. As long as one maintains a
negative relationship with the event that caused his or her suffering, the
suffering has potential to exist in a harmful way. However, the negative
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relationship does not have to exist forever. It is possible for a person to alter his
or her attitude about a traumatic experience.
When an individual is able to live through the suffering of remembering a
trauma and alter his or her attitude about a traumatic experience, posttraumatic
growth occurs. Positive posttraumatic growth often co-occurs with PTSD (Levy
& Clark, 2008). Although many people disregard the possibility of posttraumatic
growth, the idea that tragedy can trigger personal transformation is an ancient
thought occurring throughout the course of major religions, Greek tragedy, and
other literatures (Tedeschi & McNally, 2011). Typically there are five domains in
which trauma may elicit personal growth: renewed appreciation for life, new
possibilities, enhanced personal strength, improved relationships with others,
and spiritual change (Tedeschi & McNally, 2011). An example of posttraumatic
growth is found in a study performed by Sledge, Boydstun, & Rabe (1980). This
study interviewed aviators that were shot down, imprisoned, and tortured for
years by the North Vietnamese, and of those interviewed, 61.1% reported that
they had benefited psychologically from the experience. Among the reports, the
aviators said that imprisonment had produced positive changes in their
personalities, increased their self-confidence, and taught them what was truly
important in life (Tedeschi & McNally, 2011). It is true that certain variables
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mediate posttraumatic growth, but it is a real possibility for anyone suffering
from a traumatic experience. Furthermore, it is even more promising for PTSD
victims that symptom severity is positively correlated with the degree of
posttraumatic growth. A preventative, pharmacological treatment for PTSD
would eliminate any chance for posttraumatic growth or personal change
because the traumatic event would not have a great impact on the victim’s life.
Posttraumatic growth is another life altering effect of the trauma that would be
prevented from developing along with the memory of the experience or the
emotions involved. Perhaps PTSD is not a biological malfunction but a
purposeful occurrence. Through dealing with one’s trauma and suffering in an
open, honest manner, an individual can experience posttraumatic growth and
find meaning in his or her life after the trauma.
Although it is true that humans are subject to biological, psychological,
and sociological conditions, certain feats are unexplainable. It is possible for an
individual to live through unimaginable suffering, even if completely
undeserved. In Frankl’s Man’s Search for Meaning, Nietzsche is quoted as saying,
“He who has a why to live for can bear with almost any how” (Frankl, 1985). It
may be unexplainable, but any individual can live through any amount of
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psychological suffering as long as he or she has the will to do so, which is
illustrated through research on posttraumatic growth.
In respect to the values of memories and emotions as well as the
possibility of posttraumatic growth, it may be that the argument for the
elimination of suffering is not as simple as originally thought. The question
quickly evolves from a purely scientific one regarding the definition and
treatment of suffering to a question fully invested in the essence of whom the
patient is and his or her meaning in life. Before a person can begin to
contemplate a treatment for suffering, he or she must decide what he or she
believes his or her experiences are worth. Is it best to eliminate one’s pain or fully
invest in the experience and work to overcome the suffering that accompanies
the traumatic memory?
It is entirely possible to derive value from suffering, and suffering does
not have to be eliminated in order to find meaning post trauma. It is important
for an individual to live through his or her suffering because each individual has
a say in what he or she will become and the changes that he or she can influence.
After all, “A human being is not one thing among others; things determine each
other, but man is ultimately self-determining. What he becomes—within the
limits of endowment and environment—he has made out of himself” (Frankl,
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1985). Regardless of what today holds, tomorrow is a new day with new
opportunities. A man has the choice to behave like a “swine” or a “saint.” The
individual can either choose to sit by thinking about the past or live in the
present and push beyond the suffering to find meaning. The search for meaning
may be accomplished by avoiding suffering through a pharmacological
treatment. However, by intentionally focusing on experience and intentionally
working through the hardships, the search for meaning becomes so much more
informed. This choice is the individual’s to make. In the case of PTSD, the victim
may choose to numb his or her memories by accepting treatment or he or she
may deny pharmacological treatment and seek to find meaning in life after the
trauma.
The ability to use one’s suffering to find meaning is predicated on one’s
attitude. If it is not possible for a person to find a reason to overcome his or her
suffering, it is nearly impossible for him or her to see any meaning that will
result from such suffering (Frankl, 1985). In this case, the PTSD victim most
definitely should accept treatment and proceed on with his or her life because
there is no value in suffering by itself. However, if the victim believes that he or
she may find meaning in life after the trauma, then a treatment may not be
necessary. Frankl explains, “The way in which a man accepts his fate and all the
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suffering it entails, the way in which he takes up his cross, gives him ample
opportunity—even under the most difficult circumstances—to add a deeper
meaning to his life” (1985). Frankl suggests that suffering provides an individual
the unique opportunity to find meaning in life, and through the discovery of
one’s meaning he or she is able to alter his or her relationship with the traumatic
memory. Life is not special in itself, but living for a meaning and having the
ability to live for a purpose is special. Although it is difficult to see initially,
suffering may influence a new meaning in life and a new purpose of living.
Through the discovery of meaning, a victim is able to alter his or her
relationship with a traumatic memory and use his or her suffering as fuel for the
good that may lie ahead. It is quite difficult to see how a mother’s viewing of her
child’s death can be turned into human achievement or how a war veteran may
be able to transform his actions of killing in Vietnam into personal growth, but
these instances do exist. Frankl makes this clear when he says, “even the helpless
victim of a hopeless situation, facing a fate he cannot change, may rise above
himself, may grow beyond himself, and by so doing change himself. He may
turn a personal tragedy into a triumph” (1985). No matter the scenario, an
individual has the opportunity to alter his or her attitude about the situation. For
example, due to her child’s death, the mother previously mentioned may wish to
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adopt an orphaned child. In doing so, the mother would provide the orphan
with a home and a nurturing upbringing so that he or she is aware of the justices
and the injustices of the world. Likewise, the war veteran may be able to speak as
an advocate to young men and women on the value of a life and in doing so,
save the lives of others. It is truly difficult to overcome suffering, but if one can
look at the future ahead rather than the events of the past, he or she may find
meaning in life and alter this or her relationship with the traumatic memory.
Any event has the power to be transformative, and every experience
contributes to who you are as a human being. The events that cause PTSD or
other degrees of suffering are extremely powerful due to the emotional nature of
the event. Perhaps this leads an individual to think that these events must be
eliminated from one’s memory. Still one may choose to use these events as
powerful tools to make a personal change and create meaning. The greatest
amounts of suffering have the potential to lead to the greatest degrees of
posttraumatic growth, but this is only possible if one is willing to look past his or
her suffering, alter his or her relationship with the traumatic event, and
ultimately find meaning. If one is able to maintain the attitude necessary to find
meaning, then there is most definitely value to the process of working through
and overcoming the suffering that results from a traumatic event.
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Through hard work and a commitment to life, I believe that any
individual has the ability to overcome suffering and find meaning in life.
Research shows that approximately 60% of people suffering from PTSD show
evidence of posttraumatic growth, and that the degree of posttraumatic growth
is positively correlated with the severity of PTSD symptoms (Tedeschi &
McNally, 2011). This finding illustrates that it is possible to find a meaning in life
and a reason for living, in the midst of the suffering that may ensue. The
previous section’s analyses support that there is value in suffering alone but that
there is tremendous value in overcoming suffering by way of dealing with one’s
current state and working to improve one’s self on a daily basis. For those who
are committed to dealing with their suffering in a real, honest, and upfront
manner, there is an opportunity to grow from any experience and find meaning.
Although I believe everyone can find meaning beyond trauma and
suffering, I also realize that some individuals need more help than others in
finding meaning. If it is true that every person has the ability to grow from any
experience, why do only 60% of PTSD victims show evidence of posttraumatic
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growth? What about the other 40%? I believe that some individuals need help in
their search for meaning. Some individuals suffer to such an extent that they
cannot complete effortless, daily tasks or muster enough courage to simply go to
bed at night. How are these individuals supposed to find meaning in such a
broken life? These are the types of patients that need help to carry on; these
individuals need a treatment to get them back into living life. Although current
drugs threaten the victim’s memories and emotions, for these particular
individuals the costs associated with the drug may be outweighed by the chance
of the victim returning to a version of their premorbid functioning.
Subsequently, a return to daily functioning may allow the individual to partake
in activities that lead to the discovery of meaning in one’s life that was inhibited
by PTSD. In certain circumstances, I believe that a treatment for PTSD is needed
in order for the victim to have the ability to move past his or her suffering and
redeem his or her memory of the trauma.
The possibility of treating PTSD, as well as other mental disorders,
ultimately relies on the victim’s situation and decision of whether or not he or
she can live an agreeable life without a treatment. If a person truly believes that
he or she will not be able to function, and he or she is willing to lose the
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memories or emotional connections to the trauma involved, I do not believe that
a person should be denied a treatment if one is available. Treatment for PTSD
should be considered on a case by case basis due to the high stakes for those
wishing to pursue a treatment strategy. Patients should be made aware of the
possibilities of recovery without a treatment. It remains true that growth can be
obtained for most PTSD cases without a pharmaceutical treatment. Yet, certain
cases of PTSD are so inhibiting that they disallow the patient to live his or her
life. Regardless of these patients’ knowledge of potential side effects and the
wider implications of these effects on society as a whole, if a treatment for PTSD
is made available for those victims who cannot even sleep at night because their
traumatic experience haunts their dreams, it can be expected that these
individuals will choose the treatment option despite the individual and societal
costs.
While uncertain that this scenario will occur due to ethical considerations,
if there is enough pressure and a growing market for a PTSD, or suffering, drug
to be developed, I believe that it is likely that a PTSD drug may become
available. In preparation for this possible scenario, it is important for people to
give serious consideration to how such a treatment could be implemented.
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Although this drug may be intended for those victims with incredibly severe
versions of PTSD, it is likely that treatment will become universally available for
all persons affected by PTSD.
Whether the treatment for PTSD were to become universal or simply
remain available to those suffering from the most severe cases of PTSD, there are
issues regarding how such a treatment could be implemented. For instance, for
such a treatment to be implemented the patient would need to be able to give
informed consent. This would be quite difficult seeing that the majority of
experimental treatments for PTSD would need to be used within a certain time
frame following the trauma. Because most individuals who go on to develop
PTSD do not have the mental aptitude to give informed consent, the possibility
of treatment is complicated even further. There are many concerns surrounding
potential implementation strategies for preventative as well as reactive
treatments for PTSD.
While I believe that a PTSD drug is far from market, I realize that certain
people need a treatment in order to move on with their lives. Once need becomes
too large for society to ignore, a treatment for PTSD is likely to be given more
attention. Before this occurs, it is important to be proactive and call attention to
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the possible complications concerning the implementation of a PTSD medication.
In the following section, I will provide an overview of the possible issues about
PTSD treatment implementation as well as a hypothesis of how a PTSD
treatment may be implemented justly.

III.

How could a treatment for PTSD be implemented
ethically and justly?

It may be true that science is far from curing PTSD, but it may also be true
that society is close to seeing a treatment for PTSD on the market. It is yet to be
seen when or if a treatment for PTSD will be developed and implemented.
However, it is never too early to think how a drug may be implemented and how
the implementation of that drug may affect society. If one believes that he or she
cannot function without medication or that the reclaiming of their previous life is
greater than the cost of losing one’s memory, a PTSD treatment may be
developed to diminish or eliminate PTSD symptoms when the drug is given
immediately after the trauma. Such a drug could potentially alleviate suffering
for millions of individuals. This sort of treatment has ethical concerns due in
part to the potential inability to give informed consent. A solution to this ethical
dilemma may be to provide a preventative rather than reactive drug for PTSD. If
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you could give each individual about to enter a potentially traumatic
environment or situation a drug which would prevent any chance of the
development of PTSD, PTSD would cease to be an issue. However, this
implementation strategy also has widespread ethical concerns. For instance, how
does one decide which individuals receive the treatment? What constitutes a
traumatic environment or situation? How would a preventative treatment for PTSD
affect society? These are important questions to consider and the aim of this
section. I believe that there are individuals in absolute need of a treatment for
PTSD. However, I do not think there is a foolproof process of implementation for
such a treatment.
Theoretically, the prevention of PTSD may be accomplished either by
providing a treatment prior to the trauma or by providing a treatment in
response to a traumatic event. Henry et al. (2007) reports that the strength of a
memory is directly correlated with the release of endogenous hormones such as
adrenaline. During a stressful situation, an over-release of adrenaline occurs and
this results in elevated levels of noradrenaline. This elevated level is what is
thought to perpetuate the over consolidation of the memory and cause PTSD
(Henry et al., 2007). If a treatment, such as a beta-adrenergic antagonist, is used
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to prevent this process of over-consolidation from occurring, the enhanced
memory as well as the PTSD symptoms may be eliminated. Thus, it is thought
that a preemptive attempt to treat PTSD would be the most effective. Following
this line of thought, several studies have successfully prevented the development
of PTSD by administering a preventative treatment before subjecting the subject
to the experimental trauma (Cahill et al., 2002; Maheu et al., 2005; Reist et al.,
2001; van Stegeren et al., 2005).
Strictly looking at the neurological mechanisms through which it is
believed that PTSD results, it seems that treatments for PTSD should be
preventative in nature. Yet, in a social context, this conclusion is not so easily
reached. If a treatment is given prior to a traumatic experience, it must be known
that there is a good chance that a traumatic event will occur. In the case of many
traumatic events, such as natural disasters and car accidents, this knowledge is
unavailable. Yet in certain circumstances, it may be concluded that a traumatic
event is likely to occur. Individuals in the fire, law enforcement, military, and
rescue fields may benefit from a preventative treatment of PTSD because these
professions typically increase the probability of being exposed to a traumatic
event. Individuals such as these may be treated with short-term memory
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suppressors prior to entering a situation that could potentially put them at risk
for developing PTSD. This initially sounds like a fantastic option, but one must
remember that any current PTSD treatment either blunts the victims’ memories
or the emotions involved with those memories. These remain to be huge side
effects not to be taken lightly. Additionally, both short and long term side effects
of repeated usage of such a drug remain unknown.
Although a preventative treatment for PTSD may be most effective, it
may not be the most advantageous treatment strategy. If one attempts to reduce
suffering through preemptive intervention, many questions arise. First, how do
you decide who receives a preventive PTSD treatment? What are the criteria for
being eligible for such a treatment? Perhaps you only administer such a
treatment to individuals whose jobs entail regular exposure to traumatic
experiences. If this is the case, how do you decide what regular exposure to
traumatic experiences means? Because of the importance of memories to an
individual and society, a line must be drawn so that the elimination of memory,
whether traumatic or not, is not as accessible as the elimination of a headache.
In addition to the unsolved questions regarding implementation, the
preventive strategy to treating PTSD may have wide ranging impacts on society.
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If large groups of people are treated for PTSD, they will not suffer as much. They
also may not remember the events that occurred or their emotional feelings
about those events. Since the people who may be treated pre trauma are the
individuals in rescue, protection, and law enforcement roles, these side effects
may create huge consequences for society. For example, in the court of law, these
individuals often have to give testimony, but this could not be justly achieved if
their memory of the situation had been impaired in any way. This problem
would become much larger if this form of PTSD treatment was made available to
a wider group of people. A preemptive treatment strategy for PTSD does not
only have implementation issues but may negatively impact society as well.
The other viable option for treating PTSD, as previously mentioned, is to
do so after the traumatic event has occurred. This treatment also aims to reduce
the amount of noradrenaline produced in response to stress. Although providing
treatment post stress is less effective in reducing the consolidation of memory, it
still has memory blunting effects and may be an effective strategy for treating
PTSD. Treating PTSD victims post trauma removes much of the issue of
determining who should and should not be treated. For instance, with this
treatment strategy, not every firefighter, police officer, or soldier would be given
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a memory repressing drug. Instead, only those that have been exposed to an
excruciating trauma or wish to receive the treatment after the trauma would be
given the drug. This strategy would reduce the amount of emotionally blunted
memories. Thus, the impact on society would not be as great, and the
implications of PTSD treatment outside that of the victim’s life are not
controversial.
A post trauma PTSD prevention strategy must be advantageous for the
individual in order to be implemented. At the conclusion of section III, I
concluded that the majority of PTSD victims grow from the traumatic experience
causing their PTSD symptoms but that some individuals do not show any
posttraumatic growth and require a PTSD treatment in order to determine
meaning from their traumatic experience. It is not possible to reduce the
consolidation of memory years after the trauma has occurred. In order to reduce
PTSD symptoms, the treatment must be administered either prior to or
immediately following the traumatic experience. Thus, a reactive treatment to a
traumatic event does not allow the individual the opportunity to respond to the
event either positively or negatively. Unlike a preventative treatment, the post
trauma treatment strategy does still allow the victim or those connected to the
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victim to determine how severe the traumatic experience has been and if the
victim should be given a memory repressing treatment. Although there is no
sure fire method of determining if a person will develop PTSD in isolation or in
combination with posttraumatic growth, with the reactive treatment strategy,
each victim has the ability to choose whether or not to receive treatment.
A reactive PTSD treatment strategy thus limits the impacts of a PTSD
treatment on society while allowing for an individual to choose whether to
endure the suffering and traumatic memory or to administer a PTSD symptom
reducing treatment. This is not to say that this strategy is without concern. Like
the preemptive PTSD treatment strategy, the reactive PTSD treatment strategy
has an issue with implementation, informed consent. Following a traumatic
experience, especially one that results in the most severe forms of PTSD, the
victim is not likely to be in any emotional state to give informed consent. This
inability of a victim to give informed consent is a major hesitation in the
treatment of PTSD.
Informed consent is the medical avenue through which a treatment may
be made available to a patient. However, informed consent requires the patient
to decide what his or her best option is. Does the patient wish to be treated or
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not? Supady, Voelkel, Witzel, Gubka, and Northoff (2011) state that decision
making is the crucial psychological process in informed consent. The United
States, as well as other Western countries, adheres to a mandatory model of
autonomy. This means that patients have the right to make informed choices for
themselves. The traditional, paternalistic model of medical decision making
differs from the autonomous model by mandating doctors to choose which
option is most advantageous for the patient. According to this view, patients are
cognitively and emotionally unprepared to make decisions in their best interest
(Botti, Orfali, & Iyengar, 2009). Although United State’s doctors still take the
Hippocratic Oath to “follow that system of regimen which, according to my
ability and judgment, I consider for the benefit of my patients,” it has been
decided that patient’s values should also be given greater value than the
knowledge of the medical staff (Oath of Hippocrates, ca. 400 BC/1910). This is in
large part due to the Kantian philosophy that people are not merely a means, but
an end in themselves. A doctor may aid in the decision process, but ultimately,
the decision is not the doctor’s to make. Thus, the mandatory model of autonomy
presupposes that patients know their risk aversion and desired quality of life
better than doctors. Individuals must make educated, informed decisions. This
may be accomplished with the help of doctors’ advice, but a patient must also
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reflect on his or her own values and decide whether or not to take a treatment. If
the patient is not in a position to make this decision, it is up to the patient’s
family or the doctor to make this tough decision.
Although the paternalistic model of medical decision making has
technically departed from medical practice in the United States, glimmers of it
still exist. Doctors still have a great impact on their patients’ decisions. There are
a few doctors who choose to give patients, and their families, the best available
data, untainted by the doctor’s perspective, in order to let the family and patient
determine the best option as it fits with their value system. Most doctors, realize
that complex decisions are emotionally taxing, and the patient may not be
prepared to fully make the decision. Ubel and Loewnestein (1997) recap an area
of cognitive psychology research that has shown that people are rapidly
overwhelmed by having to consider more than a few options, and quickly resort
to simplifying strategies that ignore pieces of the information. For this reason,
many doctors choose to provide their professional perspective on the possible
options at hand. Hopefully, through this unbiased medical advice, the family can
make an educated decision in determining if the patient should or should not
receive the treatment.
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It is important for the doctor to remain emotionally detached from the
patient’s available options, but it is also important for the doctor to provide
information concerning all possible future outcomes in addition to his or her
medical advice to the patient and the patient’s family. I believe that a PTSD
victim can only make an informed decision on whether or not to receive
treatment if he or she is able to understand all of the options for his or her future.
This is a difficult concept to grasp, but I believe that the decision to be treated for
the possible development of PTSD is also difficult. It should not be an easy
decision to completely eliminate the emotional connections it has on a memory
or to eliminate the opportunity of growing out of an experience. All in all,
informed consent should be taken very seriously especially for those individuals
that are at risk for developing PTSD. I believe that the traumatized individual is
the only person that has the ability to fully make the decision to administer a
treatment but also realize that this option is not available for the greatest types of
traumas.
In the cases where the traumatized individual is unconscious or
emotionally unavailable to give informed consent, I believe that it is up to the
family and friends to make the decision for the victim. In my opinion, the doctor
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should not be making such a decision. The expression of PTSD is not a life
threatening illness but a lifestyle altering disorder. It is terrible that some
individuals perpetually suffer from a traumatic experience, but it is also
miraculous for individuals to overcome their suffering and experience
posttraumatic growth through the discovery of meaning. When a doctor is faced
with the decision of providing a memory repressing drug and altering a patient’s
remembrance of a major event in his or her life, I hope that the doctor will let life
take its course rather than imparting his or her own beliefs on the situation.
The process of treating PTSD is a complicated one. It is not beneficial for
society to universally provide a memory-repressing drug for all people that may
develop PTSD. In fact, I believe that a treatment for PTSD symptoms only has the
potential to be beneficial as long as it leads the individual to personal growth. I
personally believe that the premature treatment of PTSD symptoms, whether
prior to or following a trauma, is not the route to develop. I believe that the
search for meaning and the process of aiding people in dealing with their
suffering and traumatic memories are the area in which research should be
focused. Helping the suffering by way of a pharmacological treatment is an
admirable goal, but the discovery of a pharmacological treatment to reduce
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PTSD symptoms is not the only way to provide help. The methods in which we
can help those suffering from PTSD are numerous. A pharmacological treatment
may be the answer some day, but today there are too many issues and ethical
concerns to develop a treatment. Some of the questions and concerns regarding
preventative treatments may be resolved, but I do not believe that society is at a
place to implement such a treatment. It is important to keep focusing on asking
the tough questions surrounding the treatment of disorders such as PTSD.
Without giving thought to the issues at hand, no treatment will ever surface,
PTSD will continue to remain untreatable, and the 40% of PTSD victims that do
not experience posttraumatic growth will continue struggling through life.

The past three sections covered a myriad of topics including scientific
research, animals as research subjects, the value of overcoming human suffering,
posttraumatic growth, and the implementation of possible PTSD treatments.
Additionally, I have explored the thoughts of others while sharing what my
beliefs are regarding the issues. However, I do not believe I have fully integrated
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the past three sections or conveyed what I believe the next steps are for the
researchers, medical professionals, victims, and general public in dealing with
PTSD. In the final section of this afterword, I will address these questions and
begin to bring this thesis to a close.

IV.

What does this all mean, and what is next?

In For the Time Being, Annie Dillard explains that “to save a life is to save
the entire world” (2000). This statement may be seen as support for a PTSD
preventing drug. After all, a pharmacological treatment for PTSD may save the
quality of life that the trauma victim is used to living. However, this statement
may also be seen as support for the process of overcoming suffering. Perhaps it is
not up to a drug, but rather up to the individual and his or her family and
friends to save a life. It may be that we are all called to help each other while we
are in need, and if we each can save, or help, a single life, then we will save the
world.
After conducting my own research and exploring the ethical questions
surrounding pharmacological PTSD treatments, I have formed to the opinion
that a preventative treatment for PTSD should not be made available universally
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because: 1) there are high costs associated with the altering of traumatic
memories, 2) there would be tremendous implementation problems in
administering a preventative drug, and 3) In my opinion, the process of
overcoming suffering is a vital part of life. I believe that there are way too many
costs and limitations associated with a preventative treatment of PTSD.
Additionally, I would rather encourage growth by bettering the therapies
available than eliminating suffering with a pill. I also believe that the search for a
pharmacological treatment for PTSD should not completely be abandoned. If a
drug is someday developed to rid an individual of a single memory of an event
from years prior, I believe that this is an avenue to treating PTSD without the
tremendous costs, ethical concerns, and implementation issues.
Although there are 5.2 million people suffering from PTSD in the United
Sates alone, and many of these individuals’ symptoms will remain chronic, I
believe that there is great value in working to change one’s relationship to the
traumatic experience. Suffering is a common misfortune of the world, no
individual should be forced to endure it in any shape or form, and it is an
admirable goal to attempt to rid the world of the memories that influence
suffering. However, I do not believe the mechanism used to alleviate suffering
should be a pill that attempts to purge the world from traumatic memories.
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Suffering serves as a main avenue for the discovery of meaning in life and the
pursuit of Magis. I believe that God allows free will, and thus suffering. A person
can only recognize injustice in comparison to justice. Although freedom allows
us to influence suffering, it also allows us to be Gods hands; “It is up to us, what
God will see and hear, up to us, what God will do. Humanity is the organ of
consciousness of the universe…Without our eyes, the Holy One of being would
be blind” (Dillard, 2000, p.196). While today’s world, and every life in this world,
is full of suffering and injustice, it can be changed without numbing the effects of
evil actions or erasing one’s memories. A drug is not needed to eliminate
suffering.
My recommendation is to concentrate one’s efforts on improving the
cognitive and behavioral therapies available to treat PTSD and to concentrate
pharmacological research efforts on a reactive treatment to PTSD rather than a
preventative treatment. Currently, the efficacy of therapies used to treat PTSD is
questionable to say the least. PTSD has a lifetime prevalence of approximately
6.8% in the United States and a 12 month prevalence of 3.8% (Adamec, Muir,
Grimes, & Pearcey, 2007). This equates to 5.2 million people suffering from PTSD
in the United States. Of these 5.2 million people, 30% of them will still be
suffering from PTSD symptoms 10 years from now, and their symptoms are
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likely to remain chronic (Langevin, De Salles, Kosoyan, & Krahl, 2010). These
statistics show that the current treatments of treating PTSD are not effective at
this time and that greater research on ways to develop therapeutic treatment
options as pharmacological options should be completed.
In regards to possible pharmacological treatments, I believe that the area
of focus needs to be on reactive treatments for PTSD. Such a treatment would
lessen PTSD symptoms, even years after the trauma has occurred. This may seem
like a fairytale treatment, but this is where the research has begun to shift.
Research has attempted to single in on how long-term memory is stored, and the
claim has been made that PKM-zeta is a crucial protein kinase in this process
(Lisman, 2012). Furthermore, research has shown that the inhibition of this
kinase, with ZIP, which is a membrane permeable peptide inhibitor of PKM-zeta,
leads to the reduction of memory. When ZIP is administered immediately
following an event or weeks to months afterward (when remembering the event)
the subsequent memory of the event is eliminated (Shema, Kacktor, & Dudai,
2007; Cohen et al., 2012). PTSD treatment research is moving in a positive
direction. However, I still believe that the goal should not simply be to cure an
individual’s symptoms but to help the individual grow out of his or her
experiences and find meaning out of his or her suffering.
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Although the research has begun to shift away from developing a
preventative treatment for PTSD, it is still important to continue asking the
difficult questions about potential treatments. It is important to realize that there
is value in overcoming suffering. Although every individual should be able to
function normally, suffering is a vital part of the human condition. Posttraumatic
growth can be achieved in response to this suffering. In order for people to
continue asking difficult questions, society needs a fundamental change of
attitude. Frankl points out that “Life ultimately means taking the responsibility
to find the right answer to its problems and fulfill the tasks which it constantly
sets for each individual” (1985, p. 98). Each individual must realize his or her
speck of the world and work to redeem his or her place. This may be support for
an individual suffering from PTSD, a PTSD victim addressing his own struggles
in a real and honest manner, or it may not have anything to do with PTSD.
Regardless of circumstance, each individual has the ability to redeem a small
portion of the world. Without question, the world can be a dark place, but
sometimes it takes suffering to truly see the light that may be uncovered in the
darkness. PTSD research must continue, but regardless of its outcome,
individuals must continue working through suffering in a real and honest
manner.
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Concluding Remarks:
How a thesis helps find meaning…
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Upon completing this thesis project, I can honestly say that no other class,
project, or assignment has contributed as much to my learning and personal
growth as this project. Through the course and past fourteen months, I have
learned much about PTSD and the possible treatments of the disorder, realized
that the philosophical exploration of questions is just as important as scientific
studies, and most of all, uncovered much about myself. Through the completion
of this thesis, I have gained a better understanding of what I wish to do in the
future and what my search for meaning entails. Just as I began this thesis project
with a hope to integrate my beliefs into my thesis work, I look to conclude this
thesis with a hope to continue questioning the topics that I have explored in this
thesis, to continue to grow as a person, and to move forward in the search of
meaning.
My thesis project began with the scientific research I conducted on The
effects of propranolol, a non-selective β-adrenergic antagonist, on rat behavior in an
animal model of posttraumatic stress disorder. This study allowed me the
opportunity to grow as a neuroscience student, to gain valuable research
experience, and to learn about a psychological disorder that is important to me
and an issue for those suffering from the disorder. Although I did not support
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the hypotheses that I set at the onset of the study, I found significance in other
areas of the study. According to the data collected, propranolol does not have a
significant effect on PTSD-like symptoms in rats. The data also suggests that the
animal model may not have sufficiently produced a model of PTSD. However,
the present study did yield data concerning the time course of the presentation of
PTSD-like symptoms, and also provided data suggesting that laboratory animals
may perpetually be in a state of anxiety, potentially an animal-version of PTSD.
This study challenged me to take the neuroscience knowledge I have learned in
the classroom and apply it to real world issues. Through the process of designing
and then carrying out a study, I have gained valuable research experience that I
can take with me into my next stages of life. Through this study and greater
thesis project, I have learned a lot about what it takes to further knowledge
through scientific research.
The study I conducted, as well as the greater thesis, revealed a lot of
information about PTSD that I had not previously known. I have learned a great
amount about the possible neurobiological mechanisms through which PTSD
may be influenced. Additionally, I have learned that there is not and cannot be,
at the current time, an adequate treatment for PTSD. Although there have been
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many advances in research regarding the topic, no treatment has proved
effective for the preventative or reactive treatment of the disorder minus
significant side effects. On a more elementary level, this thesis has opened my
eyes to the prevalence of PTSD and the issues that it creates for those suffering
from the disorder and others involved in their lives.
As I mentioned earlier, PTSD is an important topic for me. Although I do
not have a relative suffering from PTSD, I do have three uncles and an aunt in
the military, and my future career plans may include the military as well. I
believe that I am blessed for not having to see them suffer from this disorder, but
I know that they are at a greater risk for developing PTSD at some point during
their lives. As I have gained a greater knowledge of the disorder, I have become
aware of the issues that it may create and the struggles that are involved with
overcoming one’s symptoms. I also know that I am passionate about easing
suffering and continuing the work I have began in this thesis. In many ways, this
thesis has influenced my outlook on the future.
Although this thesis has not changed my career plans of becoming a
physical therapist, it has managed to change my outlook on the way I will live
my life going forward. The researcher’s primary influence on my future is the
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latent idea of allowing life to happen and learning from every experience. In the
study, I did not find the results that I believed I would, but I did find other data
that can inform PTSD research as well as the field of neuroscience. I believe that
life often times throws curve balls, and although one may be completely
prepared, things can go contrary to planned. As I move forward, I will prepare
for the future, but I will also learn from every instant, be flexible with the course
that life takes, and be ready to take advantage of each stage of life.
The philosophical questions raised in The Afterword of this thesis, influence
my life even more so than the research at the foundation of my thesis. Through
the philosophical questions, I have learned that it is most important to ask tough
questions and to formulate one’s own answers to those questions. From the
scientific standpoint, it seems great to eliminate suffering and it is fascinating
that a drug can numb the emotional context of an experience. However, this
great scientific goal does not seem quite so marvelous when one asks the
question: is the cost of eliminating memories or the emotional aspects of memory
worth the benefit of reducing suffering? This question, forces an individual to
think of the value of his or her memory, the value of his or her emotions, and the
problems that may arise for society if a treatment is found. Nothing is as simple
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as it seems. It is important to not accept things as right or wrong simply because
one opinion is the general consensus. Instead, each person must ask his or her
self tough questions and form his or her own answers to those questions. It is
through the thought processes that one takes in answering such questions that
truly informs the individual. Although the development of a treatment for PTSD
is not a single person’s decision, the administration of a treatment does require
one’s consent. Before consenting to a memory altering treatment, each person
with the potential of developing PTSD must think of the consequences, both
good and bad, that the treatment may have. As I move forward beyond Regis, I
will continue to ask hard questions, to search for the answers to these questions,
and ultimately to find meaning in my work and life.
Along with the continuation of asking hard questions, I will also continue
to take action towards the reduction of suffering. It is through action that a
person can find his or her meaning in life. Regardless of any trauma one has
endured or any hardships that lie ahead, it is crucial for an individual to
proactive and reactive. Each person must take action by pursuing the
achievement he or she wishes to see and striving for his or her own personal
growth. Regardless of one’s beliefs on the value of suffering, it is true that today
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is not yesterday, and every day that we live, we move closer to death. One must
not live in the past or for the future; we must all live for today. Ultimately, by
living in the moment and asking the hard questions that inform one’s life, one
will find his or her meaning in the world, which is the art of Magis.
Magis, Latin for more, is the Jesuit concept of living a life for the greater
glory of God and continually striving to improve the world. The needs of the
world become visible only through straining to see the way that the world truly
is. One must strain to see the injustices that lie in front of them and the suffering
that affects the lives of our friends, families, and fellow persons. About 7 billion
people live on Earth, and each person has his or her own hardships and
experiences with suffering. If you cannot imagine the quantity of 7 billion,
simply multiply yourself as well as all your qualities, attributes, experiences, and
imperfections by 7,000,000,000. The world is a massive place, and much of the
time the individual gets lost in the expansiveness of the world. This is
exemplified when Dillard cites Stalin as saying, “One death is a tragedy; a
million deaths are a statistic” (2000). All too often, suffering is generalized into a
common phenomenon. If one is truly looking to live out the Magis, he or she will
seek to find and make just the injustices in the world, and suffering will not
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simply become a statistic. Although one is not able to redeem the entire world,
no person is free to take no part in it. Each person must find his or her purpose
by searching for the Magis every day and redeeming his or her own speck of the
world.
With the conclusion of this thesis, I near the end of my time at Regis
University, and as I prepare to leave Regis, I am determined to remain passionate
about the value of learning, the pursuit of knowledge, and the belief that asking
hard questions leads to greater understanding. These are the things that Regis
has instilled in me, and the reason that I chose to write a thesis that would test all
facets of my intellect. I have also chosen this thesis topic because I found an
injustice in world and hoped to redeem a small part of the injustice. Throughout
this thesis, I have attempted to play a small role by creating awareness of PTSD
and searching for a treatment. Through this thesis project, I have searched for the
Magis, and I hope that this work has managed to redeem a speck of the world.
Regardless of where life leads me after graduation, I will continue to search for
the Magis, to redeem small specks of the world, and to run with full speed
towards excellence. Furthermore, I promise to never lose sight of the man I have
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become as a product of my experiences, my education, my relationships, and this
thesis project.
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